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ABSTRACT 
Men are at higher risk of developing both atherosclerotic cardiovascular disease and abdominal aortic 
aneurysm (AAA). Actions of sex steroids are hypothesized to underlie these gender differences. 
Testosterone, the major androgen, reduces atherosclerosis in male animal models but is suggested to 
promote AAA formation. However, the role of the androgen receptor (AR) in mediating these effects 
of androgens is unknown. Further, the physiological metabolic actions of androgens in females are 
unclear. Estradiol, the major estrogen in females, reduces atherosclerosis in female animal models and 
can be metabolized to 2-methoxyestradiol, a biologically active metabolite, in the vascular wall. 
This thesis aimed 1) to determine the role of the AR in the atheroprotection by testosterone in male 
mice, and 2) to investigate the physiological, AR-dependent actions of androgens in the development 
of atherosclerosis in female mice, and 3) to investigate the role of the AR in the development of AAA 
in male mice, and 4) to examine whether 2-methoxyestradiol affects the development of 
atherosclerosis in female mice.    
Male and female AR-deficient mice (AR
-
 and AR
-/-
) on apolipoprotein E-deficient background were 
generated using Cre/loxP technology. Male AR
-
 mice fed a high-fat diet displayed accelerated 
atherosclerosis and reduced atheroprotection by testosterone. Female AR
-/-
 mice fed a high-fat diet 
displayed accelerated atherosclerosis associated with several features of the metabolic syndrome 
including obesity, insulin resistance and dyslipidemia. In an angiotensin II-induced model of AAA 
formation, male AR
-
 mice were protected from the development of AAA while displaying increased 
atherosclerosis, and testosterone increased AAA formation in controls, but not in AR
-
 mice. In 
addition, 2-methoxyestradiol treatment reduced atherosclerotic lesion formation in female 
apolipoprotein E-deficient mice. 
In conclusion, AR-mediated actions of androgens play important roles in both male and female mice. 
In males, AR-mediated actions of testosterone reduce atherosclerosis and promote AAA formation. In 
females, AR-mediated effects of androgens are important for metabolism and protects against 
atherosclerosis. Further, the estradiol metabolite 2-metoxyestradiol may hold promise as an 
atheroprotective drug.  
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ABBREVIATIONS 
AAA Abdominal aortic aneurysm 
ApoE  Apolipoprotein E 
AR Androgen receptor 
CHD Coronary heart disease 
COMT Catechol-O-methyltransferase 
CVD Cardiovascular disease  
DHT 5α-dihydrotestosterone 
DXA Dual Energy X-ray Absorptiometry  
ER Estrogen receptor 
IFNγ Interferon γ 
IL Interleukin 
HDL High-density lipoprotein 
LDL  Low-density lipoprotein  
MMP Matrix metalloproteinase  
Orx Orchiectomy 
Ovx Ovariectomy 
PCOS  Polycystic ovary syndrome 
SMC  Smooth muscle cell 
TNFα Tumor necrosis factor α 
VCAM-1  Vascular cell adhesion molecule-1 
WT Wild-type 
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INTRODUCTION 
CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) denotes disorders of the heart and blood vessels and includes e.g. 
coronary heart disease (CHD), cerebrovascular disease, and peripheral arterial disease. CVD is the 
leading cause of death in the world, causing about 30% of deaths globally, and more than 40% of 
deaths in Europe.
1
 The global burden of CVD is increasing and CVD will remain the leading cause of 
death worldwide in 2030.
2
 The underlying cause of the majority of clinical CVD events is 
atherosclerosis.
3
 
Atherosclerosis 
Atherosclerosis is a disease characterized by the formation of thickenings of the innermost layer of the 
arterial wall. These thickenings or atherosclerotic lesions/plaques develop in large and medium-sized 
arteries preferentially at sites with turbulent flow and shear stress, typical of branches, bifurcations, 
and curvatures.
4
 Atherosclerotic lesions are characterized by inflammation, lipid accumulation, cell 
death and fibrosis. Clinical complications of atherosclerosis may arise from flow-limiting stenoses, but 
most of the fatal clinical events are caused by the rupture of a plaque. Such rupture exposes the pro-
thrombotic material in the plaque to the blood and causes thrombotic occlusion of the artery at the 
rupture site.
5
 Risk factors associated with atherosclerosis include age, gender, dyslipidemia, 
hypertension, diabetes mellitus, and smoking.
6
 However, it is not completely understood how these 
risk factors affect the complicated mechanisms that underlie the formation of atherosclerotic lesions.  
Fatty streaks  
Before the concept of atherosclerosis as an inflammatory disease was proposed by Russell Ross, the 
formation of atherosclerotic lesions was regarded as a consequence of hypercholesterolemia with lipid 
accumulation and smooth muscle cell proliferation in the vascular wall as characteristic features.
7
 
However, during the last decade the concept of atherosclerosis as an inflammatory disease has become 
increasingly recognized.
8
 
The initiation of atherosclerotic lesion formation is thought to involve activation of the endothelium in 
the arteries. This activation increases the permeability of the endothelium, which leads to infiltration 
and subsequently retention of low-density lipoproteins (LDL) in the intima,
9
 initiating an 
inflammatory response.
10
 
In the inflamed intima modification of LDL, through oxidation
11
 or enzymatic cleavage, releases lipids 
that can induce endothelial cells to express leukocyte adhesion molecules.
12
 These adhesion molecules 
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recruit circulating platelets which further activate the endothelial cells.
13
 Activated endothelial cells 
express several types of leukocyte adhesion molecules, causing leukocytes to roll along the vascular 
surface and adhere at the activated site. One of these adhesion molecules is vascular cell adhesion 
molecule-1 (VCAM-1), which is up-regulated in response to hypercholesterolemia.
14
  
Leukocytes such as monocytes and lymphocytes, bind to VCAM-1 on the activated endothelium. 
Once attached, these leukocytes migrate into the intima in response to chemokines produced in the 
inflamed intima.
8
 Other cytokines or growth factors  produced by the inflamed intima, transform the 
infiltrating monocytes into macrophages. These macrophages then take up oxidized LDL via their 
scavenger receptors, and are transformed into foam cells. The inflammatory response in the intima 
also induces migration and proliferation smooth muscle cells (SMC).  
The foam cells are able to present T-lymphocyte-specific antigens on their surface that activate T cells. 
Such activated T cells produce mainly pro-inflammatory cytokines, interferon-γ (IFN-γ) and tumor 
necrosis factor α (TNF-α). IFN-γ is a macrophage stimulating cytokine that activates macrophages to 
produce TNF-α and interleukin-1 (IL-1). These cytokines together induce production of many 
inflammatory and cytotoxic molecules in macrophages and vascular cells. This further increases 
inflammation and promotes recruitment of additional monocytes and T cells. Together the 
macrophages and T cells form fatty streaks, which are precursors to the more advanced lesions.
8
 Fatty 
streaks can form early in life, and have been observed already in fetal aortas.
15
 However, such fatty 
streaks do not cause clinical symptoms and may progress to more advanced lesions or regress.
8
  
 Advanced lesions  
As fatty streaks grow and progress to a more advanced lesions, more inflammatory cells and lipids 
infiltrate the vessel wall. Advanced lesions have a more complex structure than fatty streaks (figure 1); 
in the centre of the plaque, foam cells and extracellular lipid droplets form a core region which is 
covered by a fibrous cap of SMCs and a collagen-rich matrix.
5
 In the shoulder region, the plaque 
grows and macrophages and T cells accumulate. Other inflammatory cell types in the lesion include 
dendritic cells, mast cells, B cells, and natural killer T cells. The lesion can become even more 
complex, when foam cells in the core region go into necrosis and cholesterol is deposited as 
cholesterol clefts.   
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Figure 1. Cryosections of the aortic root from mice showing a fatty streak and an advanced lesion stained for macrophages 
(A, B) and stained with Masson (C,D). The fatty streak mostly consists of macrophages stained brown-red (A), while there 
are almost no macrophages present in the advanced lesion (B). Masson staining shows no collagen (blue color) within the 
fatty streak (C), while the advanced lesion (D) has a collagen-rich matrix (blue), a necrotic core (gray) which is covered by a 
fibrous cap containing smooth muscle cells (red).   
Even though the plaque grows into the intima, the lumen diameter remains constant due to remodeling 
of the artery wall, which leads to a compensatory enlargement of the vessel lumen.
16
 However, some 
lesions continue to grow into the lumen and become fibrous, with a small lipid pool, abundant SMCs 
and few macrophages. These stenotic lesions may narrow the lumen and restrict blood flow, 
particularly under situations of increased cardiac demand. Such lesions lead to ischemia, causing 
symptoms such as angina pectoris.
17
  
Plaque rupture 
The fibrous cap that covers the necrotic core prevents contact between the pro-thrombotic material in 
the plaque and the blood. However, if inflammation persists, extensive remodeling of the plaque and 
destabilization of the fibrous cap occurs, which eventually leads to rupture or erosion.  In these 
vulnerable plaques, activated immune cells including macrophages, T cells and mast cells produce 
molecules that can destabilize lesions. Pro-inflammatory cytokines such as IFN-γ and TNF-α inhibit 
collagen formation, while matrix metalloproteinases (MMPs) and other proteases degrade the 
collagenous cap. These changes weaken the fibrous cap and make it prone to rupture. When the plaque 
ruptures, pro-thrombotic agents within the plaque are exposed to the blood. This launches a 
coagulation cascade that leads to thrombus formation. If unresolved, the thrombus can occlude the 
vessel and restrict blood flow or it can follow the blood stream to a smaller vessel. In both situations, 
Fatty streak Advanced lesion
Macrophage
staining
Masson 
staining
A B
C D
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the thrombus can cause acute symptoms. In the coronary arteries, thrombi can lead to myocardial 
infarction, whereas in the arteries that supply the brain, it can cause ischemic stroke.
5
   
 
Mouse models of atherosclerosis  
Much of the understanding of the pathogenesis of atherosclerosis derives from animal models. One 
such model is the laboratory mouse. However, atherosclerosis does not develop spontaneously in 
mice. Some strains of inbred mice, especially C57BL/6 mice, can develop atherosclerotic lesions when 
fed a diet that promotes hyperlipidemia; this diet is commonly referred to as the Paigen diet and 
contains saturated fat, cholesterol and cholate. The inclusion of cholate in the diet is controversial 
because it induces an inflammatory response.
18, 19
 Even after prolonged feeding of Paigen diet, the 
lesions in C57BL/6 are small, restricted to the aortic root and do not generally evolve beyond lesions 
containing foam cells.  
The possibility to genetically modify the mouse genome has provided tools for the generation of 
animal models in which complex atherosclerotic lesions develops. These mouse models have in 
common that they either overexpress or lack genes involved in the regulation of lipoprotein 
metabolism.
20
 Two of these mouse models have become widely used, namely low-density lipoprotein 
receptor-deficient (LDLR
-/-
) mice and mice that lack apolipoprotein E (ApoE
-/-
).  
LDLR
-/- 
mice consuming chow diet develop a modest hypercholesterolemia and no atherosclerosis, but 
respond to fat feeding by developing hypercholesterolemia and atherosclerotic plaques. These lesions 
develop throughout the aorta, with large lesions in the aortic root and coronary arteries.
21
 The lesions 
formed in LDLR
-/- 
mice mainly consist of foam cells; features of advanced lesions such as necrotic 
cores are only generated after prolonged feeding of high fat diets. The LDLR
-/- 
mouse has a more 
human-like lipoprotein profile than wild-type (WT) mice with most plasma cholesterol in LDL.    
ApoE
-/-
 mice develop spontaneous hypercholesterolemia and atherosclerosis. Lesions are formed 
throughout the aorta including the aortic root, the ascending aorta, the aortic arch, the abdominal aorta, 
and the innominate and coronary arteries.
22
 The progression of lesions in this strain can be greatly 
accelerated by an atherogenic diet and these lesions become complex containing foam cells, necrotic 
cores, and fibrous caps. In ApoE
-/-
 mice most plasma cholesterol is carried in very low-density 
lipoprotein, rather than in LDL as in humans.
20 
Abdominal Aortic Aneurysm  
Abdominal Aortic Aneurysm  
Abdominal aortic aneurysm (AAA) rupture is a significant cause of mortality for adults >60 years and 
has been estimated to be the tenth commonest cause of mortality in Western Countries, causing 
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approximately 2% of all deaths.
23
 General AAA screening programs have been shown to reduce 
mortality in men aged >65 years,
24, 25
 and are now introduced in many countries
26
. AAAs usually do 
not cause clinical symptoms until rupture occurs, but rupture may lead to death within minutes due to 
major bleeding.
27
  
In humans, AAA most frequently occurs in the infrarenal part of the aorta (figure 2). An AAA is 
defined as a maximal aortic diameter of ≥3 cm, although other definitions have been used.28, 29 
Epidemiological studies have identified several risk factors that associate with AAA, including male 
gender, age, smoking, hypertension, obesity, and family history. Several of these risk factors are also 
associated with atherosclerosis and patients with AAA frequently exhibit increased atherosclerosis. 
Whether this association is causal or simply due to shared risk factors is unknown.
24
  
 
Figure 2. Abdominal aorta with an aneurysm. Aneurysms most frequently occur in the infrarenal part of the aorta in humans 
and in the suprarenal part of the aorta in mice. 
The mechanisms underlying the initiation and formation of AAA are still poorly understood. 
However, histological features of AAA include chronic adventitial and medial infiltration of 
inflammatory cells, elastin degradation, and medial attenuation.
30
 In AAA, inflammatory cells 
(neutrophils, T cells, B cells, macrophages, mast cells, NK cells) infiltrate all layers of the vascular 
wall.
31-34
 These cells produce several inflammatory factors including cytokines, chemokines, 
leukotrienes, reactive oxygen species, and immunoglobulins. In the early stages of AAA formation, 
mainly Th1 cytokines such as IFN-γ are secreted. Later, in established AAA, the cytokine expression 
is altered and dominated by Th2 cytokine expression, especially IL-4, IL-5 and IL-10.
35
 In this 
inflammatory environment, endothelial cells, SMCs, fibroblasts or macrophages are all capable of 
producing enzymes that degrade extracellular matrix proteins such as collagen and elastin. These 
enzymes include MMPs, serine proteases (e.g. t-PA, u-PA, plasmin and neutrophil elastase), and 
cysteine proteases (cathepsin D, K, L, and S). When released, these enzymes degrade collagen and 
Suprarenal
Infrarenal
Abdominal aorta
Aneurysm
Kidney
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elastin in the aortic vessel wall. The resulting collagen degradation and elastin fragmentation together 
with smooth muscle cell apoptosis leads to aortic expansion and subsequent aneurysm development.
30
  
Animal models of AAA 
Mouse models of AAAs have been developed, employing different methods to produce the disease, 
including genetic manipulation,  chemical induction and angiotensin II (AngII) infusion.
36
 The genetic 
manipulations are spontaneous or engineered and include defects in extracellular matrix maturation, 
increased degradation of elastin and collagen, disturbed cholesterol homeostasis and enhanced 
production of angiotensin peptides. The chemical approaches include e.g. luminal infusion of elastase 
and periaortic incubations of calcium chloride.  
The models in which AngII is infused into ApoE
-/-
 or LDLR
-/-
 mice demonstrate features of human 
AAA.
36
 Administration of AngII at doses of 500-1000 ng/kg per minute, leads to AAA in the 
suprarenal part within the 28-day infusion period.
37
 The maximal dose (1000 ng/kg per minute) often 
increases blood pressure.
38, 39
 However, a blood pressure increase is not required for formation of 
AAA, because interventions that eliminate AAA do this independently of the effects on blood 
pressure.
40
  
 
GENDER DIFFERENCE IN CARDIOVASCULAR DISEASE 
Gender difference in coronary heart disease and atherosclerosis  
There is a marked gender difference in life span throughout the world. Men in most countries have 
shorter life expectancy than women. In fact, men live on average 5.6 years shorter than women in 
countries above a minimal economic development (Gross Domestic Product
 
(GDP) in U.S. dollars, 
$3000 per capita).
41
 This gap in life expectancy is to a large extent driven by a male predisposition to 
clinical CVD events caused by atherosclerosis. Coronary heart disease deaths in men exceed those in 
age-matched women by 2.5-to -4.5-fold up until the age of 75. The age-specific CHD death rates 
curves are parallel for men and women, but with a 5-10 year early head start in men. The reason for 
the gender difference in CHD is not known, but is likely to involve genetic, hormonal, and/or lifestyle 
factors or a combination of mechanisms. The male early head start of atherosclerosis and its 
complications could reflect biological processes early in life (e.g. perinatal androgen surge in boys) or 
early in the pathogenesis of atherosclerosis.
41-43
 Indeed, gender differences are found in endothelial 
function, lipid loading of human monocyte-derived macrophages, and abdominal fat deposition, all of 
which are processes related to the atherogenesis.
43
  
Gender differences are also found in animal models of atherosclerosis. Males develop earlier and more 
extensive atherosclerosis independent of lipid levels in diet-induced models both in non-human 
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primates
44
 and rabbits.
45, 46
 Although data are divergent, gender differences are also observed in mouse 
models of atherosclerosis involving ApoE
47
 and LDL receptor deficiency.
48, 49
  
Gender difference in abdominal aortic aneurysm 
In epidemiological studies, male gender is consistently identified as a strong risk factor associated 
with AAA.
50-52
 Men have a 4-fold increased risk of AAA in population-based studies
23, 53
 compared 
with women.  
Several of the rodent models of AAA formation show a gender difference comparable to that of 
humans.
39, 54, 55
 In AngII-induced AAA in ApoE
-/-
 and LDLR
-/-
 mice, males are more susceptible to 
aneurysm development than females; AAA develops in 80% of the males compared with 
approximately 20- 30% in female mice.
39
 
 
SEX STEROIDS 
Sex steroids 
Sex steroids are steroid hormones that are produced predominately by the testes in men and by the 
ovaries in women. Sex steroids include androgens and estrogens, and progesterone is sometimes 
included as a third class of sex steroids. In addition to the gonadal sex steroids, the human adrenal 
cortex produces substantial amounts of sex steroid precursors (C19 androgens) which can be locally 
converted into androgens and estrogens in both sexes. However, in contrast to humans and higher 
primates, adult rodents (e.g. rats and mice) produce little or no androgen precursors from the 
adrenals.
56
 Androgens and estrogens exert important effects on growth, development, and 
morphological differentiation, as well as on the development and regulation of sexual and reproductive 
behavior in both sexes.
57
  
Androgens  
In males, testosterone is the major potent circulating androgen with more than 95% derived from 
testicular secretion. Testosterone is synthesized in the Leydig cells of the testes and circulates bound to 
albumin and sex hormone binding globulin. There are three phases with high testosterone production 
in a male´s life. The first phase takes place during fetal development, leading to differentiation of the 
male reproductive organs. The second phase occurs shortly after birth, and the third phase starts at 
puberty and continues through adulthood. After peaking at approximately 20 years of age, the 
testosterone levels begin declining with age.
58
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In females, androgens are secreted from the ovaries and androgen precursors from the adrenal cortex. 
Testosterone is the most important androgen also in females, but testosterone levels in the circulation 
are less than 1/10 of those of young men.
59
 
Activation of the androgen receptor (AR) mediates an important part of the physiological effects of 
testosterone.
41, 43
 The AR is stimulated either directly by testosterone or by its locally formed 
metabolite 5α-dihydrotestosterone (DHT). Although not present at high levels in the circulation, DHT 
is the main source of androgenic activity in many tissues as it is the most potent endogenous androgen. 
Aromatization of testosterone to estradiol provides an alternative pathway for the effects of 
testosterone. Estradiol exerts its effects in turn via signaling pathways distinct from the AR, most 
importantly via the estrogen receptor α (ERα). Testosterone may also exert effects independently of 
the classical sex steroid receptors
41
(figure 3).   
 
 
 
 
Figure 3. Pathways for the effect of testosterone. AR=androgen 
receptor, ERs=estrogen receptors. 
 
The androgens affect most organs and tissues in the body. Their actions include development of 
reproductive organs and secondary sex characteristics, regulation of reproduction, behavior, muscle 
mass and strength, and distribution of body fat. These effects are physiologically important and well 
characterized in males. In contrast, the physiological actions of androgens in females have received 
less attention.
60, 61
  
The androgen receptor 
The AR is a 110-kDa nuclear protein with 918 amino acid residues. It is located on the X chromosome 
and ubiquitously expressed in tissues.
41, 43
 The AR gene has three major functional domains, as 
illustrated in Figure 4. The N-terminal domain, which serves a modulatory function, is encoded by 
exon 1. Exons 2 and 3 encode the DNA-binding domain. The ligand-binding domain is encoded by 
exons 4-8. The AR belongs to the nuclear receptor super-family together with receptors for other 
steroid hormones such as thyroid hormone, vitamin D and retinoic acid. These receptors are ligand-
activated transcription factors with a highly conserved structure. In the classical model of steroid 
hormone action the binding of hormone to these receptors induces an allosteric change. This allows 
Estradiol
AR
Other pathways
Testosterone
ERs ?
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the hormone-receptor complex to pass into the nucleus and bind to high affinity sites on the chromatin 
and affect transcription.
62
  
 
 
Figure 4. Structural organization of the AR gene and protein 
 
As a homodimer, the androgen-AR complex can induce or suppress androgen-responsive genes by 
interacting with specific hormone responsive elements known as androgen responsive elements.
63
  
In addition to the classical genomic effects, there are indications of rapid, non-genomic effects of sex 
steroids. The non-genomic effects of androgens involve the activation of second messenger signal 
transduction cascades, including increases in cytosolic calcium and activation of protein kinase A, 
protein kinase C and MAPK. These non-genomic rapid effects of androgens are suggested to be 
mediated by a hitherto uncharacterized membrane receptor.
41, 64, 65
 
Androgen receptor deficient mice 
Animal models of androgen insensitivity are useful for studies investigating the physiological AR-
dependent actions of androgens. In the 1970s, Lyon and Hawkes reported an X-linked gene for 
testicular feminization (Tfm) in the mouse.
66
 The Tfm mice carry a single nucleotide deletion in exon 
1 of the AR gene, which leads to premature termination of the AR.
67
 Tfm mice are infertile and their 
testes are small and abdominally located in the inguinal region, as in some patients with complete 
androgen insensitivity syndrome.  
Beside the Tfm mouse, there are several genetically modified mouse models with ubiquitous knockout 
of the AR (ARKO).
68
 Since male ARKO mice are infertile and the AR is located on the X 
chromosome, generation of ARKO male and female mice uses Cre-loxP technology. This involves a 
Cre transgenic mouse that expresses Cre recombinase ubiquitously and a mouse strain in which a part 
of the AR is flanked by loxP sites. This part of the gene, typically an exon, is referred to as floxed. 
When these mouse strains are crossed, the offspring will express Cre recombinase which recognizes 
and cuts out the floxed exon, resulting in knockout of the AR. 
gene 1 2 3 4 5 6 7 8
exon
DNA-binding Ligand-bindingN-terminal 
COOHNH2protein
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Table. Description of the constructs and metabolic phenotypes of the different ARKO mouse 
models 
Ref  Floxed 
exon 
Promoter of 
Cre 
recombinase 
Result of 
recombination 
Detectable 
AR 
protein  
Obesity 
reported 
Lipids 
69     
Japan 
 Exon 1 
 
CMV Deletion of exon 1, 
insertion of early 
stop codon 
No Yes Cholesterol ↔ 
Triglycerides ↔ 
70        
USA 
 Exon 2 
 
β-actin 
 
Deletion of exon 2, 
insertion of early 
stop codon 
No Yes Cholesterol ↔ 
Triglycerides ↑ 
71  
Belgium 
 Exon 2 PGK Deletion of exon 2, 
insertion of early 
stop codon 
No No  (see 
Paper I 
and III) 
Not determined 
72 
Australia 
 Exon 3 CMV In-frame deletion 
of exon 3 
Yes No Not determined 
 
The phenotype of the different ARKO males is dominated by female-like external organs, absent male 
internal genitalia as well as testes that are small and abdominally located. In addition, these mice have 
increased LH levels and decreased levels of testosterone.
68
 Two of the ARKO mice models exhibit late 
onset of obesity (see Table). There are also reports of osteopenia in the male ARKO model.
73, 74
  
The ARKO female mice have been less studied. They are fertile, but with lower follicle numbers and 
impaired mammary development and produce half the number of pups per litter. At 40 weeks of age, 
the ARKO female mice are infertile because of complete loss of follicles.
75-78
  
Estradiol and metabolism of estradiol   
Estradiol is the most important circulating estrogen in premenopausal women, and more than 95% of 
serum estradiol derives from ovarian secretion.
59
 However, several other organs and tissues produce 
estradiol from sex steroid precursors, including adipose tissue, skin, endometrium, vaginal mucosa, 
breast, liver, blood vessels, and heart.
79
 Estradiol levels vary greatly during the ovarian cycle, until 
menopause when serum levels of estradiol fall to levels below those found in men.
80
 The actions of 
estrogens are fundamental in female reproductive function and metabolism.
81
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Figure 5. Metabolism of estradiol. GT=glucurunosyltransferase, ST=sulfotransferase, EAT=estrogen acyltransferase, 
COMT=catechol-O-methyltransferase. 
Elimination of estradiol is mainly mediated via metabolism into water-soluble compounds that are 
eliminated by the kidneys (urine) and liver (faeces). It includes glucuronidation, sulfation, 
esterification, or O-methylation of estradiol or its hydroxylated metabolites. The hydroxylation of 
estradiol is mediated by several CYP450 isoforms. Most of the oxidative metabolism of estradiol takes 
place in the liver, but some isoforms of CYP450 are expressed locally in the periphery. Through the 
action of CYP1A1 and CYP1B1, estradiol is metabolized to catecholestradiols, such as 2-
hydroxyestradiol and 4-hydroxyestradiol. The catecholestradiols can then be methylated via enzymatic 
O-methylation into 2-methoxyestradiol and 4-methoxyestradiol by the enzyme catechol-O-
methyltransferase (COMT)
79
 (figure 5). Several estradiol metabolites exert biological effects, which 
may be dependent or independent of the classical ERs.
82
 During the past decade, much interest has 
focused on 2-methoxyestradiol, a potent inhibitor of cell proliferation.
83
  
 
ANDROGENS AND CARDIOVASCULAR DISEASE IN MALES 
Androgens, atherosclerosis and coronary heart disease in men 
Low serum testosterone levels have been shown to associate with an adverse metabolic risk profile 
including increased abdominal fat mass, increased levels of total and LDL-cholesterol and 
triglycerides, reduced levels of high-density lipoprotein (HDL) cholesterol, insulin resistance, and 
hyperglycemia.
58, 84-87
 Indeed, low testosterone levels in men associate with increased 
atherosclerosis.
85-89
 Further, data from prospective longitudinal studies report increased all-cause 
mortality in men with low testosterone levels, although the results on the association with CVD 
mortality are conflicting.
90-93
 To date, there are no studies demonstrating a significant association 
between testosterone levels and incident (fatal/non-fatal) CHD events in men, whereas low 
testosterone levels recently have been linked to increased risk of stroke.
94
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Methoxyestradiols
COMT
CYP450s
sulfates
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Data from studies of patients undergoing androgen deprivation therapy for treatment of prostate cancer 
have provided useful insight into the role of androgens in cardiovascular health. Androgen deprivation 
therapy, including the use of gonadotropin-releasing hormone agonists and/or AR-antagonists, 
increases body weight, reduces insulin sensitivity, and elevates serum cholesterol and triglyceride 
levels.
95
 Recent studies also suggest that androgen deprivation therapy may increase the risk for 
cardiovascular disease and cardiovascular mortality.
96-98
  
Androgens and atherosclerosis in male animals   
Results from animal models support that testosterone confers a beneficial effect on atherogenesis in 
males. Testosterone treatment reduces atherosclerosis development in orchiectomized (Orx) male 
rabbits fed a pro-atherogenic diet.
99-101
 Similarly, testosterone treatment reduces atherosclerosis in 
male ApoE
-/-
 mice
102, 103
 and LDL-R
-/-
 mice.
104
 Possible mechanisms include reduction of total 
cholesterol and elevation of HDL levels and reduction of pro-inflammatory cytokines.
41, 43, 102, 104, 105
  
The putative pathways for the atheroprotective actions of testosterone in male mice have not been well 
defined. The beneficial effect of testosterone on atherogenesis is mediated via AR-independent 
pathways, involving aromatization of testosterone to estradiol. Nathan et al.
104
 found that an aromatase 
inhibitor blocked the effect of testosterone in LDL-R
-/-
 mice, indirectly indicating that the AR pathway 
is less important for atheroprotection by testosterone. However, no study has addressed the role of the 
AR pathway, for the effect of testosterone on atherosclerosis in mice.  
Androgens and abdominal aortic aneurysm in males 
Despite epidemiological evidence that male gender is a strong risk factor for AAA, there are few 
studies examining the role of androgens for AAA formation. As Orx protects against AngII-induced 
and elastase-induced AAA formation in male rodents,
55, 106
 it is feasible that androgens promote AAA 
formation. Contrasting the results from experimental studies, a recent population-based study in men 
showed that lower levels of free testosterone, but not total, levels were associated with a higher risk of 
AAA.
53
 It is still unknown whether physiological doses of testosterone can accelerate AAA formation, 
and whether the AR would mediate such an effect. Studies on AAA formation in AR deficient mice 
have not yet been performed.  
 
ANDROGENS IN FEMALES 
The physiological metabolic effects of androgens in females are poorly known
60, 61
 and the importance 
of androgens in women’s cardiovascular health remains to be clarified.61 Studies on the actions of 
androgens in females have been hampered by difficulties of assessing low serum levels of androgens 
as well as determining appropriate, physiological doses for replacement.
61, 107
 The fact that 
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ovariectomy (Ovx) entails loss of both androgens and estrogens is frequently overlooked, potentially 
contributing to an underestimation of the role of androgens.  
 
Hypo- and hyperandrogenism in women 
To date, a definition of androgen deficiency in women is lacking, and consequently the symptoms, 
signs, and clinical outcomes associated with androgen deficiency are not well characterized.
60, 61
 There 
are several conditions that have been shown to associate with low testosterone levels in women. These 
include ovarian dysfunction (e.g. oophorectomy, chemotherapy, and radiation), adrenal dysfunction 
(e.g. adrenal insufficiency and adrenalectomy), hypothalamic-pituitary dysfunction, and drug-related 
effects (e.g. corticosteroids, antiandrogens, oral contraceptives, oral estrogen replacement therapy).
108
 
Although available data are scarce, they suggest that androgen deficiency in women is characterized 
by symptoms such as diminished sense of well-being or dysphoric mood, fatigue, sexual dysfunction, 
decreased muscle strength and bone mass.
60
 However, the metabolic consequences of androgen 
deficiency in women are not well defined.  
In women with polycystic ovary syndrome (PCOS, affecting 6-10% of all women), a cluster of 
cardiovascular risk factors (e.g. insulin resistance, abdominal obesity, hyperlipdemia and 
hypertension) is associated with hyperandrogenism.
109
 Although most evidence suggest that insulin 
resistance rather than hyperandrogenism plays a key role in the pathogenesis of PCOS,
110
 the link 
between hyperandrogenism and the metabolic syndrome has led to the paradigm that androgens exert 
adverse cardiovascular and metabolic effects in women.
111, 112
 Whether there is an association between 
high androgen levels in women with PCOS and increased risk of cardiovascular events is a matter of 
controversy.
113
  
Androgens and atherosclerosis in female animals 
Previous experimental studies on androgens and atherosclerosis in females are few. Treatment studies 
show inconsistent results; some studies suggest that androgen administration accelerates atherogenesis 
in females,
114, 115
 while other studies suggest atheroprotective effects.
102, 103, 116
  
 
VASCULAR ACTIONS OF ESTROGENS 
The male early head-start in CVD has often been explained by the protective effects of endogenous 
estrogens in premenopausal women.
41, 117
 Indeed, many reports regarding beneficial effects of estradiol 
on serum lipids, vascular endothelial function, and experimental atherosclerosis support this 
assumption. Observational studies demonstrate an association between hormone replacement therapy 
and reduced CVD risk in postmenopausal women.
80, 118
 However, two large randomized controlled 
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suggest that hormone replacement therapy could increase the risk for myocardial infarction and stroke 
in postmenopausal women,
119, 120
 questioning the belief that estrogens are protective.
121, 122
 The 
mechanisms underlying these results remain unknown and are lively debated.  
Vascular actions of estradiol  
An atheroprotective effect of estradiol is strongly supported by results from studies in animal models 
of atherosclerosis. Estradiol prevents atherosclerosis in monkeys, rabbits and mouse models of 
atherosclerosis.
123-125
 The effect is mediated through a direct effect of estradiol on the cells of the 
arterial wall, rather than an effect on the lipoprotein profile.
126
  
Several beneficial actions of estradiol on the endothelium could contribute its atheroprotective effect. 
This includes decreased expression of adhesion molecules (e.g. VCAM-1)
127
 and pro-inflammatory 
chemokines (e.g. MCP-1 and IL-8).
128
 Other beneficial actions of estradiol include decreased 
endothelial permeability
129
 and improved endothelial function (e.g. increased levels of NO and 
prostacyclin, and reduction of reactive oxygen species).
123
 Furthermore, estradiol decreases apoptosis 
of endothelial cells
130
 and accelerates endothelial healing,
131-133
 possibly involving an increase in 
circulating endothelial progenitor cells.
134-136
 Estradiol also has effects on vascular SMCs and inhibits 
migration and proliferation.
137
 In addition, estradiol decreases LDL oxidation
138
 and lipid 
accumulation in macrophages,
139
 which also could contribute to atheroprotection.  
Vascular actions of 2-methoxyestradiol 
Many of the effects of estradiol on vascular cells are mediated via a direct interaction of estradiol with 
ERs. There is also evidence that estradiol exerts biological effects via ER-independent pathways.
140, 141
 
Because estradiol is metabolized to estrogenic and non-estrogenic metabolites and estradiol 
metabolites may have biological activity, it is feasible that estradiol metabolites may play a role as 
mediators of the vasculoprotective actions of estradiol.
140
  
An estradiol metabolite of putative importance is 2-methoxyestradiol, which is a potent anti-
proliferative agent currently being evaluated in phase II clinical trials for cancer.
83, 142
 Although the 
mechanism of action of 2-methoxyestradiol requires additional clarification, it appears to be 
independent of the classical estrogen receptors.
83, 143
 2-methoxyestradiol inhibits proliferation of 
vascular smooth muscle cells as well as injury-induced neointima formation in vivo.
144
 Moreover, 2-
methoxyestradiol has vasculoprotective effects in rat models of drug-induced hypertension and 
pulmonary hypertension
145, 146
 and reduces oxidation of low-density lipoprotein in vitro.
147
 These 
findings raise the question whether 2-methoxyestradiol might have anti-atherosclerotic effects. 
However, the hypothesis that 2-methoxyestradiol can modulate atherogenesis
143
 currently remain 
untested in vivo. 
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AIMS OF THE THESIS 
 To determine the role of the AR in atheroprotection by testosterone in male mice (Paper I) 
 To investigate the physiological, AR-dependent actions of androgens on the development of 
atherosclerosis in female mice (Paper II) 
 To investigate the role of the AR in the development of AAAs in male mice (Paper III) 
 To examine whether 2-methoxyestradiol affects the development of atherosclerosis in female 
mice (Paper IV)
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METHODOLOGICAL CONSIDERATIONS 
The methods used in this thesis are described in detail in the Material and Methods sections of the 
individual papers, while a more general discussion of some of the methods is presented below.  
ANIMALS  
Since normal (WT) mice do not normally develop atherosclerosis, mice on ApoE
-/-
 background were 
used in all Papers (I-IV) included in this thesis. In Paper I, II and III, we used male or female ARKO 
mice on an ApoE
-/-
 background (ApoE-M, C57/BL6, Taconic), which were bred in our laboratory 
animal facility. In Paper IV, we used female ApoE-/- mice, which were purchased from Taconic 
(Denmark).   
DIETS 
In Paper I  and II, male and female ARKO mice on an ApoE
-/-
 background were fed a soy-free regular 
chow diet (2016; Harlan Teklad, Oxfordshire, UK) up to 8 weeks of age and then atherogenic diet 
(21% fat from lard and 0.15% cholesterol, Special Diets Services, Essex, UK) for 8 weeks to 
accelerate atherosclerosis formation. In Paper III and IV, we fed male ARKO/ApoE
-/-
 mice and female 
ApoE
-/-
 mice a soy-free regular chow diet (2016; Harlan Teklad, Oxfordshire, UK). A soy-free diet 
was used to reduce the levels of phytoestrogens in the chow. As phytoestrogens have estrogenic 
activity they could potentially influence the results in studies on sex steroid action.     
Comment: ApoE
-/-
 mice on chow diet have serum total cholesterol levels of about 20 mM. The 
atherogenic diet increases the serum total cholesterol levels to approximately 30 mM and thereby 
accelerates atherogenesis. In addition, the lesions become more advanced with necrotic cores, 
cholesterol clefts, fibrous caps, and medial extensions.  
GONADECTOMY  
We used gonadectomy; orchiectomy (Orx) of males and ovariectomy (Ovx) of females, in all papers 
(I-IV). Given the endocrine functions of the testes and ovaries, respectively, Orx decreases the 
testosterone levels in male mice, while Ovx decreases both estrogen and androgen levels in female 
animals. 
HORMONAL TREATMENT 
All hormonal treatment with sex steroids was administered through slow-release pellets (Innovative 
Research of America, Sarasota, FL) implanted subcutaneous under the skin between the ear and the 
shoulder of the mice. In Paper I and III, we used a physiological testosterone dose of 25 μg/day. We 
evaluated this dose in a pilot study; when administered to Orx mice it restored the weights of seminal 
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vesicles, ventral prostate and salivary glands to the level of sham-operated control mice. In Paper IV, 
we used an estradiol dose of 6 μg/day because several previous studies had shown that it reduced 
atherosclerotic lesion development in ApoE
-/-
 mice.
117
 This dose is supraphysiological in females. The 
2-methoxyestradiol dose of 6.66 μg is equimolar to 6 μg estradiol.  
 
EVALUATION OF ATHEROSCLEROSIS 
Atherosclerosis in mice is most frequently assessed ex vivo in aortas prepared en face or in the aortic 
root. En face prepared aortas are cleared from adventitial fat and connective tissue and cut open 
longitudinally, from the aortic arch down to the abdominal bifurcation, and pinned out flat on a dark 
material. This technique can provide information on the distribution of lesions within the aorta, but it 
cannot be used for detailed analyses of lesion characteristics. Cross-sections of the aortic root can 
provide information on both lesion size and lesion characteristics. For both techniques, it is common 
to stain for lipids to visualize the atherosclerotic lesions. To stain for lipids, we used Sudan IV stain 
for en face aortas in Papers I, II and IV, and Oil Red O stain for aortic root sections in Papers I and III. 
After staining, images were captured, and color quantified using the imaging software BioPix. 
In aortic root sections lesion characteristics can be evaluated using histological and 
immunohistochemical techniques. For assessment of lesion composition (collagen content, presence of 
necrotic core and cholesterol clefts), sections were stained with Masson´s trichrome. For evaluation of 
macrophage accumulation, aortic root sections were stained with a Mac-2 antibody. Quantitative 
analyses of collagen and macrophage content as percentage of plaque area were made using Biopix 
Software. Lesion complexity (presence/absence of necrotic core and cholesterol clefts) was evaluated 
manually. 
Comment: Mac-2 is a surface antigen expressed on mature macrophages.  
 
EVALUATION OF ABDOMINAL AORTIC ANEURYSM  
For analysis of AAA formation, the aortas were dissected free from connective and adipose tissue, and 
the presence or absence of an obvious modest or major outward remodeling of the suprarenal region of 
the aorta was determined by a blinded observer. An AAA was defined as an outward remodeling of 
the aorta in ex vivo analysis or death from major bleeding, which was confirmed in a dissection of the 
animal post mortem.
39
 We also determined the maximal outer diameter of the aorta in photos, using an 
image analysis program (BioPix Software, Göteborg, Sweden). 
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DUAL ENERGY X-RAY ABSORPTIOMETRY 
Dual Energy X-ray Absorptiometry (DXA) is a technique that was originally developed for studying 
bone parameters, but is also useful technique for metabolic phenotyping studies.
148, 149
 It measures 
bone mass, but also lean mass and fat mass. Body composition was assessed in anesthetized animals 
using a mouse DXA machine (LunarPIXImus), following the instructions of the manufacturer (Paper 
II). 
INSULIN TOLERANCE TEST 
An insulin tolerance test measures the glucose–lowering effect of a given dose of insulin. Injection of 
insulin normally decreases the blood glucose levels in an animal. In an animal with insulin resistance, 
injection of insulin has reduced or no effect on the blood glucose levels.   
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RESULTS AND DISCUSSION 
PAPER I 
In Paper I, we investigated the importance of the AR-pathway for the atheroprotective effect of 
testosterone in male mice. Because ARKO mice are testosterone-deficient, we sham operated or Orx 
the mice before puberty and Orx mice were supplemented with placebo or a physiological testosterone 
dose. From 8 to 16 wk of age, the mice consumed a high-fat diet. We examined the atherosclerotic 
lesion formation both in the aortic root and in en face preparations. 
In the aortic root, we found that sham operated ARKO mice had increased lesion area. Orx increased 
the lesion area in WT but not in ARKO mice. Testosterone significantly reduced lesion area both in 
WT (by 50%) and in ARKO mice (by 24%). Importantly, lesion area was larger in testosterone-
supplemented ARKO mice compared with testosterone- supplemented WT mice. En face analysis 
showed similar trends as in the aortic root, with some differences between different aortic regions. 
Thus, in the thoracic aorta, testosterone reduced lesion area in both WT (-53%) and ARKO (-31%) 
mice, while in the whole aorta there was an effect of testosterone in WT (-54%), but only a trend in 
ARKO mice (-21%, P = 0.075). When we assessed lesion complexity, we found that testosterone 
reduced the presence of a necrotic core in WT mice, while there was no significant effect in ARKO 
mice. We did not detect significant differences across the groups in other measures of lesion 
composition, such as cholesterol clefts, collagen content, neutral lipids, and macrophages.  
We clearly demonstrated that the AR-pathway is a major pathway for the effect of testosterone on 
atherosclerosis in our mouse model. The atheroprotective effect of testosterone in ARKO mice was 
about half of the effect observed in WT controls, suggesting that a major part of the effect of 
testosterone is mediated via the AR. These results are supported by previous studies showing that 
flutamide, an AR antagonist, inhibited most of the protective effect of testosterone on atherosclerosis 
in rabbits
150
 and that the AR agonist DHT reduced atherosclerosis in male ApoE
-/-
mice.
103
  
In contrast to the results in Paper I, Nathan et al.
104
 found that an aromatase inhibitor blocked the 
effect of testosterone in LDL-R
-/-
 mice, indirectly indicating that the AR pathway is less important for 
atheroprotection by testosterone. In a recent study, Nettleship and coworkers
151
 studied Tfm mice 
(which carry a naturally occurring AR mutant allele) on a cholate-containing diet. They found that 
exogenous testosterone reduced fatty streak formation in the Tfm mice suggesting an effect of 
testosterone that is independent of the AR. Contrasting the results of Nathan et al. the atheroprotection 
by testosterone in Tfm mice was not prevented by treatment with either the aromatase inhibitor 
anastrazole or the ERα antagonist fulvestrant. Importantly, Nettleship et al. did not treat WT controls 
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with testosterone, and thus could not determine the relative importance of AR-dependent versus AR-
independent pathways.  
Because testosterone reduced atherosclerotic lesion area in ARKO mice, these data also demonstrate 
an AR-independent action of testosterone. Aromatization of testosterone to estradiol may mediate an 
AR-independent effect of testosterone via activation of the ERs. ERα is important in atheroprotection 
by estradiol, while ERβ reportedly is less important.117 Therefore, we examined whether the decreased 
atheroprotection of testosterone in ARKO mice may be explained by decreased ERα or aromatase 
expression in the ARKO model. However, ERα mRNA expression did not decrease in the femoral 
artery or liver and we could not detect aromatase expression in either the femoral artery or the liver of 
ARKO mice. Hence, we found no support for altered ERα or aromatase expression accounting for the 
reduced effect of testosterone in ARKO mice. However, we cannot exclude the possibility of 
regulation of local aromatase expression in the ARKO model.  
It is not unlikely that the testosterone dose influences the relative importance of the different pathways 
for the testosterone effect. In Paper I, we used a physiological testosterone dose (slow-release pellets 
25μg/day), which increased both serum testosterone levels and the weights of androgen-sensitive 
organs to the level of intact WT controls. However, this dose appeared slightly supraphysiological in 
its effects on cholesterol at the study end, although the luteinizing hormone levels at the same time 
point do not support that the testosterone levels were too high. The higher testosterone dose used by 
Nathan et al (5.6 times higher than the dose used in our study) could affect the relative importance of 
the aromatization pathway. Although Nettleship et al. claimed a physiological testosterone dose, 
serum testosterone measurements revealed that the testosterone treatment was intermittently 
supraphysiological. This treatment regimen, combined with the absence of testosterone-treated WT 
controls, may contribute to an overestimation of the role of AR-independent pathways.     
We investigated possible mechanisms for the increased atherosclerosis and reduced effect of 
testosterone in ARKO mice, including serum lipids and markers of systemic inflammation. In 
agreement with previous studies,
102, 104
 testosterone treatment lowered serum total cholesterol also in 
our study. Testosterone reduced serum cholesterol in WT but not ARKO mice, suggesting a role of the 
AR in the cholesterol-lowering effect of testosterone. However, serum cholesterol did not differ 
between sham operated WT and ARKO mice despite the difference in atherosclerosis between these 
groups. This is in line with previous studies that demonstrate no difference in serum cholesterol levels 
between ARKO and WT mice.
69, 70, 152
 Hence, our data on serum cholesterol levels and atherosclerosis 
are not entirely concordant, suggesting that other mechanisms may be important.  
Testosterone has anti-inflammatory effects and these effects could be involved in testosterone´s effect 
on reducing atherosclerosis.
105
 Therefore, we analyzed seven pro-inflammatory cytokines in serum 
from sham operated ARKO and WT mice. We found increased levels of TNFα in ARKO compared 
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with WT mice. These results may suggest an effect on the inflammatory response, mediated either via 
the androgen-AR system or secondary to increased atherogenesis.  
Taken together, ARKO mice on apolipoprotein E-deficient background display accelerated 
atherosclerosis. Testosterone treatment reduced atherosclerosis in both WT and ARKO mice; however, 
the effect on lesion area and complexity was more pronounced in WT than in ARKO mice. These 
results are consistent with an AR-dependent as well as an AR-independent component of testosterone 
atheroprotection in male mice.  
 
PAPER II  
In this paper we investigated the physiological, AR-dependent effects of androgens on atherogenesis 
in female mice.  
We assessed atherosclerosis en face in 16-week-old AR
-/-
ApoE
-/-
 females, after 8 weeks on high fat 
diet.  
In the whole aorta, atherosclerotic lesion area was increased in AR
-/-
ApoE
-/-
 mice. Analysis of the 
different aortic regions showed that lesion area increased in the aortic arch, but not significantly in the 
thoracic aorta.  
Studies supporting our finding of beneficial actions of androgens in females include three mouse 
studies showing atheroprotection by supraphysiological doses of testosterone in ovarian-intact
103, 116
 
and ovariectomized mice,
102
 respectively. Other studies showing adverse or neutral effects of androgen 
treatment have been conducted in female monkeys or rabbits. In a study by Adams et al.
114
 
testosterone treatment to female monkeys increased atherosclerosis. However, in this study 
testosterone was given to ovarian-intact animals and completely suppressed ovulation, making it 
difficult to distinguish between effects of disturbed estrogen action and a direct effect of androgens on 
atherosclerosis in this study. Obsanjo et al.
115
 showed that the anabolic steroid nandrolone did not 
increase atherosclerosis versus placebo (but versus ovarian-intact controls) in ovariectomized 
monkeys. However, the authors interpreted the study and the paper is referred to
41
 as supporting a pro-
atherogenic effect of anabolic steroids in females. In female rabbits, Bruck et al.
100
 found no increase 
in intimal area by testosterone treatment.  Taken together, previous studies on androgen treatment of 
female animals are scarce and the results are conflicting. Paper II is the first study on atherogenesis in 
an animal model of female androgen-deficiency. 
In AR
-/-
ApoE
-/-
 females, increased atherosclerosis was associated with an increase in body weight and 
relative fat mass. After 10 weeks of age, body weight started to increase in AR
-/-
ApoE
-/-
 relative to 
AR
+/+
ApoE
-/-
 mice and was significantly higher in AR
-/-
ApoE
-/-
 at both 12 weeks and 16 weeks of age. 
RESULTS AND DISCUSSION 
29 
 
DEXA analysis showed that absolute and relative fat mass were increased in AR
-/-
ApoE
-/-
 mice. At the 
study end, the AR
-/-
ApoE
-/-
 mice had increased relative weights of all dissected fat depots (gonadal, 
mesenteric, and inguinal). The metabolic phenotype was further characterized by performing an 
insulin tolerance test. The glucose-lowering effect of insulin was significantly reduced in the AR
-/-
ApoE
-/-
 mice, indicating the AR
-/-
ApoE
-/-
 mice were insulin resistant. Serum total cholesterol and 
triglycerides levels were elevated at the study end, without any alteration of the lipoprotein profile.  
Hence, in addition to the augmented atherosclerosis, we found a yet unreported metabolic phenotype 
of the AR
-/-
 females characterized by a diet-induced obesity, insulin resistance and dyslipidemia. This 
is in contrast to previous studies, reporting late-onset obesity in male, but not female, AR-deficient 
mice.
76, 78, 152, 153
 In Paper II, the female AR
-/- 
mice were on an ApoE
-/-
 background and fed a high fat 
diet containing lard and it is possible that these two factors unmask a phenotype of diet-induced 
obesity in the females. Our findings demonstrate that the AR-androgen system has important 
metabolic actions in females under certain conditions. Further studies investigating the mechanisms 
underlying the obesity in AR
-/-
ApoE
-/-
 females will be required. 
We further addressed the question whether accelerated atherosclerosis in AR
-/-
ApoE
-/-
 mice was found 
only in obese mice and/or after feeding high fat diet. En face atherosclerosis in 10-week-old chow-fed 
AR
-/-
ApoE
-/-
 mice showed increased lesion area in the thoracic aorta and a similar trend for the whole 
aorta. The young (10-week-old) AR
-/-
ApoE
-/-
 mice exhibited elevated serum triglyceride levels and a 
tendency towards augmented cholesterol levels. These results showing increased atherosclerosis in 
non-obese young AR
-/-
 females on chow diet, would argue against obesity as an underlying cause of 
increased atherosclerosis. However, it cannot be excluded that already 10-week-old mice have an 
accumulation of fat in the liver, causing dyslipidemia and thereby increased atherogenesis. 
Ample data suggest that androgens play important roles in the lipid metabolism in males, but the 
molecular mechanisms are poorly understood.
154
 The results in Paper II on dyslipidemia in AR
-/-
 
females are in line with previous findings that testosterone reduces total cholesterol both in female 
ApoE deficient mice
102
 and rabbits
100
 and that DHT reduced total cholesterol, but not triglyceride 
levels in female monkeys.
155
 The results in Paper II support that androgens play an important role in 
the lipid metabolism also in females; however, dissecting the pathways involved will require further 
research.  
To evaluate the impact of the ovarian hormones on atherogenesis in AR
-/-
ApoE
-/-
 mice, we 
ovariectomized AR
-/-
ApoE
-/-
 and AR
+/+
ApoE
-/-
 mice at 4 weeks age, and assessed atherosclerosis en 
face after 8 weeks on high fat diet. Ovx increased lesion area in AR
+/+
ApoE
-/-
 mice, but not 
significantly in AR
-/-
ApoE
-/-
 mice. Because the ovaries did not protect AR
-/-
ApoE
-/-
 mice from 
atherosclerosis, we evaluated the ovarian hormone production. We found no significant differences in 
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serum estradiol, while serum testosterone levels were significantly increased in AR
-/-
ApoE
-/-
 females. 
Neither uterine nor ovarian weights differed between the genotypes.  
Our finding that the AR
-/-
 females were not protected from atherosclerosis by their ovaries could 
indicate either that: 1) factors (e.g. androgens) from the ovaries protect from atherosclerosis in the 
presence, but not in the absence, of the AR, or 2) that the ovaries in AR
-/-
 females are dysfunctional 
and do not protect from atherosclerosis. However, the serum estradiol levels were not reduced and 
uterine weights of AR
-/-
 females did not differ from controls, indicating that peripheral estrogen action 
is not severely disturbed. Hence, the loss of atheroprotection of the ovaries in AR
-/-
 females may 
support that androgens from the ovaries protect female mice from atherosclerosis. 
To confirm an atheroprotective action in females that is mediated via the AR, we ovariectomized 
ApoE
-/-
 mice and started treatment with the AR agonist DHT or placebo at 8 weeks of age, followed 
by high fat diet feeding between 8 and 16 weeks of age. Compared with placebo, DHT reduced 
atherosclerotic lesion area and serum total cholesterol levels. This finding suggests that beneficial 
effects of androgens in females are mediated via the AR. 
In summary, female AR
-/-
 mice display accelerated atherosclerosis associated with several features of 
the metabolic syndrome including obesity, insulin resistance and dyslipidemia. These results 
demonstrate that AR-mediated effects of androgens are crucial for metabolism and cardiovascular 
health in females (figure 6).  
 
Figure 6. Proposed mechanism(s) for increased atherosclerosis in female AR-/- mice.  
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PAPER III 
In Paper III, we tested the hypothesis that ARKO mice on ApoE deficient background are protected 
against the development of AAA. We infused ARKO and WT mice with AngII for 4 weeks and 
examined AAA formation. 
We found that formation of AAA was markedly reduced in ARKO compared with WT mice. In 
accordance, maximal aortic diameter was significantly lower in ARKO vs. WT mice. Our findings are 
in line with previous studies showing that Orx protects against AAA formation in rodents.
55, 106
  
Because the male ARKO mice are testosterone deficient,
156
 a testosterone treatment study was 
performed to distinguish effects of testosterone deficiency from the effects of AR inactivation. AngII-
infused Orx ARKO and WT mice were treated with a physiological testosterone dose or placebo. We 
found that testosterone treatment increased AAA formation in WT, but not ARKO mice. These data 
demonstrate that activation of the AR by a physiological dose of testosterone increases AAA 
formation in male mice. Together with data showing that the AR agonist DHT accelerates AAA 
formation in mice,
157
 our data support the notion that the AR may mediate the adverse effect of 
androgens on AAA formation. 
In line with the results in Paper I, atherosclerotic lesion area was increased in the aortic root of both 
saline- and AngII-treated ARKO mice. Our finding of concomitantly reduced AAA formation and 
increased atherosclerosis in ARKO mice is surprising because AAA formation shares important 
mechanistic pathways with atherogenesis (e.g. inflammation, oxidative stress and extracellular matrix 
degradation). In humans, AAA disease is associated with atherosclerosis as well as an increased risk 
of CVD events, although the mechanisms for this association are unknown.
24
 Importantly, there are 
differences between the two diseases; risk factors such as hyperlipidemia and hypertension are less 
strongly associated with AAA formation, whereas diabetes protects against AAA.
23
 Although the data 
on T and AAA formation are scarce, most evidence suggests that testosterone protects against 
atherosclerotic disease in both experimental and clinical studies.
41, 43
 Hence, it is possible, but not yet 
proven, that androgens have opposite effects on atherogenesis and AAA formation also in humans. 
Further investigation of the molecular mechanisms that are affected by androgens in atherogenesis and 
AAA formation will be performed in future studies by our group. 
Taken together, Paper III demonstrates that male ARKO mice are protected from the development of 
AAAs and that testosterone increases AAA formation via an AR-dependent mechanism, possibly 
contributing to the gender difference in AAA. Further, our data show that atherogenesis and AAA 
development processes are dissociated and affected in opposite directions in male ARKO mice. 
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PAPER IV  
To investigate whether the estradiol metabolite 2-methoxyestradiol affects atherosclerosis 
development, female mice were ovariectomized and treated through slow-release pellets with placebo, 
17beta-estradiol (6 microg/day), or 2-methoxyestradiol [6.66 microg/day (low-dose) or 66.6 
microg/day (high-dose)]. We found that the high-dose 2-methoxyestradiol decreased atherosclerosis 
evaluated, while the low dose 2-methoxyestradiol showed no effect.  
The finding that 2-methoxyestradiol reduced atherosclerotic lesion formation is in accordance with 
previous studies showing that 2-methoxyestradiol inhibits neo-intima formation in vivo
144
 and exerts 
vasculoprotective effects in a rat model of drug-induced hypertension and pulmonary hypertension.
146, 
158
  
The results in our study imply the possibility that 2-methoxyestradiol may partially mediate the anti-
atherosclerotic effect of estradiol in mouse models of atherosclerosis, a notion supported by the fact 
that estradiol reduces atherosclerosis in ERα-/- mice.159 Since 2-methoxyestradiol is be unable to 
activate ERs as an agonist and estradiol is protective in the absence of ERβ,117 it is possible that the 
anti-atherosclerotic effects of estradiol in ERα-/- mice are mediated by 2-methoxyestradiol. 
Interestingly, metabolism of estradiol to methoxyestradiols is critical for the anti-proliferative effects 
of estradiol on vascular smooth muscle cells.
160
 However, the role of this metabolism for the anti-
atherogenic effects of estradiol will require further studies, including estradiol treatment in 
combination with blockade or knockout of the enzymes that convert estradiol to methoxyestradiols.   
We investigated two possible mediators, serum lipids and blood pressure, for the effect of 2-
methoxyestradiol on atherosclerosis. 2-methoxyestradiol reduced serum total cholesterol levels, which 
is in line with previous observations in rats.
161
 The reduced cholesterol levels may be less important as 
they occurred in both the low- and high-dose 2-methoxyestradiol groups and atherosclerotic lesion 
area decreased only in the high-dose group. Since 2-methoxyestradiol did not affect mean arterial 
blood pressure, it seems unlikely that the reduction of atherosclerosis is mediated through a blood 
pressure mechanism. However, there are several other possible mechanisms that could contribute to 
the effect of 2-methoxyestradiol including inhibition of SMC proliferation,
144
 reduction of oxidative 
stress and oxidation of LDL,
79, 147
 as well as increased cyclooxygenase-2 expression and prostacyclin 
generation.
144, 162
  
We found that 2-methoxyestradiol shares the effects of estradiol on, for example, serum cholesterol, 
body weight gain, and uterine weight, although the effects of 2-methoxyestradiol were not as 
pronounced as those of estradiol. A possible mechanism for these estrogenic effects involves de-
methylation of 2-methoxyestradiol to 2-hydroxyestradiol, which can act as an ER agonist. Another 
possibility is that 2-methoxyestradiol, via cell-specific cofactors, can activate ERs. The role of de-
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methylation and/or activation of ERs for the atheroprotective effects of 2-methoxyestradiol in this 
study remains unclear. Thus, the answer to the question whether estradiol is effective via conversion to 
2-methoxyestradiol or whether 2-methoxyestradiol is effective via conversion to estrogenic 
compounds, or whether both mechanisms are operative, is unknown.  
In conclusion, Paper IV demonstrates that 2-methoxyestradiol, an endogenous estradiol metabolite, 
reduces atherosclerotic lesion formation in vivo. 
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CONCLUSIONS  
From the results of the Papers included in this thesis, we conclude the following: 
Paper I: ARKO mice on apolipoprotein E-deficient background display accelerated atherosclerosis. 
Testosterone treatment reduced atherosclerosis in both WT and ARKO mice; however, the effect on 
lesion area and complexity was more pronounced in WT than in ARKO mice. These results are 
consistent with an AR-dependent as well as an AR-independent component of testosterone 
atheroprotection in male mice.  
Paper II: Female AR
-/-
 mice display accelerated atherosclerosis associated with several features of the 
metabolic syndrome including obesity, insulin resistance and dyslipidemia. These results demonstrate 
that AR-mediated effects of androgens are crucial for metabolism and cardiovascular health in 
females.  
Paper III: Male ARKO mice are protected from the development of AAA and testosterone increases 
AAA formation via an AR-dependent mechanism, possibly contributing to the gender difference in 
AAA. Further, our data show that atherogenesis and AAA development processes are dissociated and 
affected in opposite directions in male ARKO mice. 
Paper IV: 2-methoxyestradiol, an endogenous estradiol metabolite, reduces atherosclerotic lesion 
formation in vivo.  
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CLINICAL IMPLICATIONS 
Manipulating the androgen-AR system in men  
Testosterone gradually declines as men age.
58
 As testosterone has important physiological effects on 
e.g. muscle, bone, fat mass and brain in men, decreased testosterone levels may contribute to the 
symptoms and signs of aging, e.g., decreased muscle mass and strength, impaired physical 
performance and cognitive function, and lack of energy. Recently, much interest has focused on 
testosterone supplementation
 
in elderly men, as evidenced by a 20-fold increase in testosterone sales in 
the United States during the 1990s.
58, 92
  
There are several short-term studies with testosterone replacement to hypogonadal and/or obese 
elderly men, reporting beneficial effects on cardiovascular risk factors such as reduced waist 
circumference, cholesterol and circulating pro-inflammatory cytokines and improved insulin 
sensitivity. Via yet undefined mechanisms, testosterone increases vasodilatation and improves 
vascular reactivity which leads to short-term beneficial effects on cardiac ischemia, angina and chronic 
heart failure.
90
 However, no long-term placebo-controlled studies have yet determined whether 
testosterone supplementation protects androgen-deficient and/or elderly obese men against 
cardiovascular disease. A recent study reported that testosterone treatment to older men was associated 
with an increased risk of cardiovascular adverse events.
163
 Hence, it is evident that the hypothesis that 
testosterone replacement leads to cardiovascular benefit needs further investigation and defining the 
pathways involved in testosterone atheroprotection in males is of great importance. The data in this 
thesis suggest that testosterone atheroprotection in male mice involves an AR-dependent as well as an 
AR-independent component. Importantly, these findings warrant confirmation in men.  
Death from AAA rupture is a major health problem, especially in men, and recently a general 
ultrasound screening of 65 year-old men for AAA was introduced in Sweden and other countries 
(started in 2008 in the Swedish region Västra Götaland). Our data showing that testosterone treatment 
of male mice increases the development of AAA in an AR-dependent manner suggests that accelerated 
formation of AAA may be a potential risk associated with extended use of testosterone 
supplementation in older men. Further, to date there are no treatment options for AAA besides 
surgery; our finding of the AR dependence in AAA formation highlights the AR as a potential target 
for interventions aimed at preventing AAA formation in men at high risk, e.g. due to strong heredity.  
The androgen-AR system is extensively manipulated during treatment of prostate cancer in men and 
androgen deprivation therapy may increase the risk of cardiovascular disease and cardiovascular 
mortality.
96-98
 However, the different treatment options for prostate cancer involve both manipulation 
of systemic androgen levels and blockade of the AR. Understanding the role of the AR in the 
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development of atherosclerosis is important for ongoing efforts to limit cardiovascular side effects of 
the different treatment regimens for prostate cancer.
164-166
  
Selective androgen receptor modulators (SARMs) are compounds that activate or inhibit the AR in a 
tissue-specific way with the goal to achieve beneficial effects on bone and muscle mass without 
adversely affecting e.g. the prostate.
167
 The findings in this thesis suggest that actions mediated via the 
AR may protect against atherogenesis, while they simultaneously increase the risk of AAA (figure 7). 
This information is essential in the design and evaluation of SARMs with a beneficial cardiovascular 
profile or SARMs that could be used in prevention or treatment of cardiovascular disease.  
 
 
Figure 7. Suggested pathways for the cardiovascular effects of testosterone in males. AR=androgen receptor, 
AAA=abdominal aortic aneurysm. 
 
Androgens to women? 
To date, a clinical definition of female androgen deficiency is lacking
60
 and the signs and symptoms 
associated with a deficient androgen action are therefore poorly understood. The development of 
female AR
-/-
 mice has provided a valuable tool for determining physiological, AR-mediated actions of 
androgens in females. In this thesis, female AR
-/-
 mice display accelerated atherosclerosis associated 
with several features of the metabolic syndrome including obesity, insulin resistance and dyslipidemia. 
These results demonstrate that AR-mediated effects of androgens are crucial for both metabolism and 
cardiovascular health in females.  
 
AR-dependent
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AR-independent 
pathways
AAA
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High levels of androgens in women with PCOS are associated with an adverse metabolic risk profile 
and increased atherosclerosis.
109
 This association has favored the idea that androgens exert adverse 
cardiovascular and metabolic effects in women.
111, 112
 However, evidence also supports an association 
between low androgen levels and atherosclerosis in women.
168-171
 Two recent studies reported that 
both high and low testosterone levels are associated with increased risk of coronary heart disease 
events in older women.
172, 173
 Thus, the clinical studies support an atheroprotective effect of androgens 
in women.   
The clinical recommendation regarding treatment and/or supplementation with testosterone in women 
is an area of disagreement.
174
 However, there is evidence from short-term studies that testosterone 
treatment to surgically menopausal women improves sexual function.
61, 175, 176
 Importantly, many of 
the published studies on testosterone supplementation in women with sexual dysfunction used 
supraphysiological doses of testosterone. In addition, there are few studies on the metabolic effects of 
a physiological androgen therapy to androgen deficient women. However, in a study by Miller et al., 
testosterone treatment improved markers of insulin sensitivity and reduced total cholesterol levels.
177
  
The results presented in this thesis highlight the importance of further research to establish an 
appropriate definition of androgen deficiency in women and to characterize the metabolic phenotype 
associated with this deficiency. In addition, our results should encourage further investigations of the 
metabolic effects of androgen supplementation, using physiological doses of androgens, e.g. to women 
after Ovx.  
 
Implications for hormone replacement therapy  
Although most experimental studies that showed anti-atherogenic effects of estrogens employed 
estradiol, two large clinical trials conducted on hormone replacement therapy in postmenopausal 
women used conjugated equine estrogens  as the estrogen component.
119, 120
 These trials unexpectedly 
demonstrated adverse cardiovascular effects of treatment, raising skepticism about whether the correct 
estrogen compound was used. Conjugated equine estrogens contain >10 estrogens extracted from 
horse urine and their exact composition remains undetermined. However, conjugated equine estrogens 
contain trace amounts of estradiol,
122
 thus generating little or no estradiol metabolites.  
The results in this thesis on anti-atherogenic activity of an estradiol metabolite lacking estrogen 
receptor activating capacity suggest that future trials should use estradiol rather than other estrogens; 
alternatively, such trials might evaluate the use of 2-methoxyestradiol for hormone replacement 
therapy. An interesting possibility is that 2-methoxyestradiol mediates anti-atherosclerotic effects 
while the parent hormone estradiol exert certain adverse effects (e.g. inflammatory activation and 
plaque instability) through the activation of ERs in the setting of established atherosclerosis.
178
 Thus, 
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further definition of 2-methoxyestradiol as a mediator of anti-atherosclerotic actions of estradiol is of 
great interest.  
FUTURE PERSPECTIVES  
Although the results reported in this thesis increase our understanding of the role of sex steroids in 
cardiovascular disease, they also lead to new questions and speculations. 
Our results showed that part of the atheroprotective effect of testosterone is mediated via the AR, but 
the exact mechanism(s) for this AR-dependent effect remains to be determined. Since inflammation is 
a corner stone in the pathogenesis of atherosclerosis and testosterone has been suggested to exert anti-
inflammatory effects, it would be of interest to perform additional studies to characterize the role of 
the AR in these anti-inflammatory effects in animal models of atherosclerosis. It would also be 
interesting to examine possible AR-mediated effects of testosterone on for example adhesion, 
infiltration, and migration of inflammatory cells in the developing atherosclerotic lesions. Studies of 
possible AR-mediated effects of testosterone on cytokine production by these inflammatory cells 
would also be of great interest.  
The endothelium is considered to play an important role in the initiation of atherosclerosis and 
endothelial dysfunction is believed to precede the formation of atherosclerotic lesions. Damaged 
endothelium is repaired by circulating endothelial progenitor cells. Low serum levels of testosterone in 
men associate with reduced number of circulating endothelial progenitor cells, which suggest a role for 
androgens in re-endothelialization. Therefore, our group will investigate whether re-endothelialization 
after endothelial injury is impaired in male ARKO mice and whether this could contribute to the 
increased atherosclerosis demonstrated in these animals. 
To further dissect the mechanisms for the AR-mediated effects of testosterone on a cellular level, it 
would be interesting to generate mice with cell-specific knockout of the AR, for example in smooth 
muscle cells, macrophages or endothelial cells, using mice that express Cre recombinase under cell-
specific promoters (such as SM22, Lys, or Tie2). These mice would then be used in atherosclerosis 
studies to investigate the importance of the AR-pathway in specific cell types. 
An issue of great importance is to perform further studies to elucidate the mechanisms that underlie 
the completely opposite effects of testosterone on atherosclerosis and AAA in male mice. One 
approach could be to run a microarray on aortas from ARKO and WT mice to identify candidate genes 
involved in these diseases that are differentially regulated. Further, cell-specific AR knockout models 
could provide valuable insight. 
One approach to further investigate the pathways for the atheroprotective effect of testosterone would 
be to treat ERα-/- mice with a physiological testosterone dose and determine the effect of testosterone 
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on atherosclerosis. The importance of genomic versus non-genomic effects of testosterone on 
atherosclerosis could also be studied by treating ERα-/- mice with testosterone together with an AR-
antagonist (e.g. flutamide).     
Further research to define the role of 2-methoxyestradiol as a mediator of the anti-atherosclerotic 
actions of estradiol should be performed. Ongoing research in our group involves estradiol treatment 
to female ovariectomized COMT deficient and WT mice, and we hypothesize that the vascular 
protective actions of estradiol is attenuated in COMT deficient mice. 
 
ACKNOWLEDGEMENTS 
40 
 
ACKNOWLEDGEMENTS 
Jag vill börja med att tacka min huvudhandledare Åsa Tivesten. Du tänker alltid positivt och vet hur 
man inspirerar en doktorand. Tack för allt du har lärt mig. Tack också för att du alltid trott på mig och 
stöttat mig i alla lägen. 
Min fästmö och blivande fru Victoria. Utan dina uppoffringar och ditt enorma stöd under dessa 5 år 
hade detta aldrig gått. Tack för din oändliga kärlek. Tack för att du ger mening åt mitt liv. Du betyder 
allt för mig. Jag älskar dig! 
Tack mamma Gunilla och pappa Bo. Ni har alltid stöttat mig och låtit mig gå min egen väg. Min 
lillebror Pär, tack för att du är en underbar bror.     
Mina blivande svärföräldrar Morgan och Britt-Marie. Tack för att ni har hjälpt mig att tänka på annat 
än forskningen. Det känns alltid lika avslappnade varje gång vi åker till er i ”Oset”. Dessutom har ni 
lärt mig oerhört mycket om allt från vedsågning till potatisodling. Tack också för hjälpen med 
klistrande av etiketter. 
Min bi-handledare Alexandra Krettek. Du måste vara världsmästare i positivt tänkande! Tack för alla 
inspirerande samtal om allt från ramskrivande till forskning i allmänt. 
I Tivesten-gruppen vill jag tacka: Annelie Carlsson, för hjälp med musavel, snittning, labbanalyser 
och för alla glada skratt. Tack också för all hjälp under många långa avslutstimmar på djurlabbet. 
Anna Wilhelmson och Camilla Alexanderson, tack för hjälp med musarbete och labbanalyser och 
för trevligt sällskap under luncher, fikapauser och konferensresor.    
Ett stort tack till alla medförfattare som gjort alla artiklarna möjliga. Thank you, Karel De Gendt 
and Guido Verhoeven for providing us with the ARflox and PGK-Cre mice. Tack också Claes 
Ohlsson, Agneta Holmäng, Göran Bergström och Jan Borén för analyshjälp och konstruktiv kritik.  
Tack Anna Karlsson, John-Olov Jansson och Suzanne Dickson för att ni lät mig prova på forskning 
i era labb. Det inspirerade mig verkligen att gå vidare och bli doktorand.  
Mike och Jon, tack för er vänskap i vårt och torrt.  
Victorias kompisar Lina och Sofie. Tack för sällskap, middagar, fika och för hjälpen med att klistra 
tusentals etiketter på provrör. 
 
 
ACKNOWLEDGEMENTS 
41 
 
Wallenberglaboratoriet är en inspirerande miljö att jobba i. Tack till alla ni som har hjälpt mig och lärt 
mig viktiga metoder. Tack till alla som vi har delat labb med här på Wallenberglaboratoriet. Tack 
Sara Sjöberg för all hjälp och för att du lärde mig alla ateroskleros-tekniker i början på min 
doktorandtid. Sedan vill jag rikta ett tack till all teknisk och administrativ personal på 
Wallenberglaboratoriet. Det är ni som får det att funka. Särskilt tack till Magnus, för all hjälp med allt 
från pennor till specialbatterier och tack för att du delar med dig av din humor. Svenne och Heimir, 
tack för IT-support.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
42 
 
REFERENCES 
1. Eurostat, Statistics in focus 2006(10). 
2. WHO, The global burden of disease: 2004 Update. 2008. 
3. Writing Group, Heart Disease and Stroke Statistics--2010 Update: A Report From the American 
Heart Association. Circulation, 2010. 121(7): p. e46-215. 
4. Ross, R., Atherosclerosis--an inflammatory disease. N Engl J Med, 1999. 340(2): p. 115-26. 
5. Hansson, G.K. and P. Libby, The immune response in atherosclerosis: a double-edged sword. 
Nat Rev Immunol, 2006. 6(7): p. 508-19. 
6. Mozaffarian, D., P.W. Wilson, and W.B. Kannel, Beyond established and novel risk factors: 
lifestyle risk factors for cardiovascular disease. Circulation, 2008. 117(23): p. 3031-8. 
7. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993. 
362(6423): p. 801-9. 
8. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 
2005. 352(16): p. 1685-95. 
9. Skalen, K., et al., Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. 
Nature, 2002. 417(6890): p. 750-4. 
10. Williams, K.J. and I. Tabas, The response-to-retention hypothesis of early atherogenesis. 
Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 551-61. 
11. Palinski, W., et al., Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl 
Acad Sci U S A, 1989. 86(4): p. 1372-6. 
12. Leitinger, N., Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr 
Opin Lipidol, 2003. 14(5): p. 421-30. 
13. Massberg, S., et al., A critical role of platelet adhesion in the initiation of atherosclerotic lesion 
formation. J Exp Med, 2002. 196(7): p. 887-96. 
14. Cybulsky, M.I. and M.A. Gimbrone, Jr., Endothelial expression of a mononuclear leukocyte 
adhesion molecule during atherogenesis. Science, 1991. 251(4995): p. 788-91. 
15. Napoli, C., et al., Fatty streak formation occurs in human fetal aortas and is greatly enhanced 
by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its 
oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest, 1997. 
100(11): p. 2680-90. 
16. Glagov, S., et al., Compensatory Enlargement of Human Atherosclerotic Coronary Arteries. 
New England Journal of Medicine, 1987. 316(22): p. 1371-1375. 
17. Libby, P., Inflammation in atherosclerosis. Nature, 2002. 420(6917): p. 868-74. 
REFERENCES 
43 
 
18. Liao, F., et al., Genetic control of inflammatory gene induction and NF-kappa B-like 
transcription factor activation in response to an atherogenic diet in mice. J Clin Invest, 1993. 
91(6): p. 2572-9. 
19. Vergnes, L., et al., Cholesterol and cholate components of an atherogenic diet induce distinct 
stages of hepatic inflammatory gene expression. J Biol Chem, 2003. 278(44): p. 42774-84. 
20. Daugherty, A., Mouse models of atherosclerosis. Am J Med Sci, 2002. 323(1): p. 3-10. 
21. Ishibashi, S., et al., Massive xanthomatosis and atherosclerosis in cholesterol-fed low density 
lipoprotein receptor-negative mice. J Clin Invest, 1994. 93(5): p. 1885-93. 
22. Nakashima, Y., et al., ApoE-deficient mice develop lesions of all phases of atherosclerosis 
throughout the arterial tree. Arterioscler Thromb, 1994. 14(1): p. 133-40. 
23. Golledge, J., et al., Abdominal aortic aneurysm: pathogenesis and implications for management. 
Arterioscler Thromb Vasc Biol, 2006. 26(12): p. 2605-13. 
24. Golledge, J. and P.E. Norman, Atherosclerosis and abdominal aortic aneurysm: cause, 
response, or common risk factors? Arterioscler Thromb Vasc Biol, 2010. 30(6): p. 1075-7. 
25. Thompson, S.G., et al., Screening men for abdominal aortic aneurysm: 10 year mortality and 
cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ, 
2009. 338: p. b2307. 
26. Wanhainen, A., Screening för bukaortaneurysm i Uppsala. Läkartidningen, 2010. 107(38): p. 
2232-2236. 
27. Upchurch, G.R., Jr. and T.A. Schaub, Abdominal aortic aneurysm. Am Fam Physician, 2006. 
73(7): p. 1198-204. 
28. Alcorn, H.G., et al., Risk factors for abdominal aortic aneurysms in older adults enrolled in The 
Cardiovascular Health Study. Arterioscler Thromb Vasc Biol, 1996. 16(8): p. 963-70. 
29. Lederle, F.A., et al., Prevalence and associations of abdominal aortic aneurysm detected 
through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs 
Cooperative Study Group. Ann Intern Med, 1997. 126(6): p. 441-9. 
30. Shimizu, K., R.N. Mitchell, and P. Libby, Inflammation and cellular immune responses in 
abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol, 2006. 26(5): p. 987-94. 
31. Cohen, J.R., et al., Neutrophil chemotaxis and neutrophil elastase in the aortic wall in patients 
with abdominal aortic aneurysms. J Invest Surg, 1991. 4(4): p. 423-30. 
32. Ihara, M., et al., Increased chymase-dependent angiotensin II formation in human 
atherosclerotic aorta. Hypertension, 1999. 33(6): p. 1399-405. 
33. Koch, A.E., et al., Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting 
an immune-mediated response. Am J Pathol, 1990. 137(5): p. 1199-213. 
34. Vanderlaan, P.A. and C.A. Reardon, Thematic review series: the immune system and 
atherogenesis. The unusual suspects:an overview of the minor leukocyte populations in 
atherosclerosis. J Lipid Res, 2005. 46(5): p. 829-38. 
REFERENCES 
44 
 
35. Schonbeck, U., et al., T(H)2 predominant immune responses prevail in human abdominal aortic 
aneurysm. Am J Pathol, 2002. 161(2): p. 499-506. 
36. Daugherty, A. and L.A. Cassis, Mouse models of abdominal aortic aneurysms. Arterioscler 
Thromb Vasc Biol, 2004. 24(3): p. 429-34. 
37. Daugherty, A., M.W. Manning, and L.A. Cassis, Angiotensin II promotes atherosclerotic 
lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest, 2000. 105(11): p. 1605-
12. 
38. Daugherty, A., M.W. Manning, and L.A. Cassis, Antagonism of AT2 receptors augments 
angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol, 2001. 
134(4): p. 865-70. 
39. Manning, M.W., et al., Abdominal aortic aneurysms: fresh insights from a novel animal model 
of the disease. Vasc Med, 2002. 7(1): p. 45-54. 
40. Manning, M.W., L.A. Cassis, and A. Daugherty, Differential effects of doxycycline, a broad-
spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and 
abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol, 2003. 23(3): p. 483-8. 
41. Liu, P.Y., A.K. Death, and D.J. Handelsman, Androgens and cardiovascular disease. Endocr 
Rev, 2003. 24(3): p. 313-40. 
42. Ng, M.K., New perspectives on Mars and Venus: unravelling the role of androgens in gender 
differences in cardiovascular biology and disease. Heart Lung Circ, 2007. 16(3): p. 185-92. 
43. Wu, F.C. and A. von Eckardstein, Androgens and coronary artery disease. Endocr Rev, 2003. 
24(2): p. 183-217. 
44. Hamm, T.E., Jr., et al., Effects of gender and social behavior on the development of coronary 
artery atherosclerosis in cynomolgus macaques. Atherosclerosis, 1983. 48(3): p. 221-33. 
45. Hayashi, T., et al., Gender differences in atherosclerosis: possible role of nitric oxide. J 
Cardiovasc Pharmacol, 1995. 26(5): p. 792-802. 
46. Holm, P., et al., Gender gap in aortic cholesterol accumulation in cholesterol-clamped rabbits: 
role of the endothelium and mononuclear-endothelial cell interaction. Circulation, 1998. 98(24): 
p. 2731-7. 
47. Caligiuri, G., et al., Effects of sex and age on atherosclerosis and autoimmunity in apoE-
deficient mice. Atherosclerosis, 1999. 145(2): p. 301-8. 
48. Egan, K.M., et al., COX-2-derived prostacyclin confers atheroprotection on female mice. 
Science, 2004. 306(5703): p. 1954-7. 
49. Tangirala, R.K., E.M. Rubin, and W. Palinski, Quantitation of atherosclerosis in murine 
models: correlation between lesions in the aortic origin and in the entire aorta, and differences 
in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient 
mice. J Lipid Res, 1995. 36(11): p. 2320-8. 
REFERENCES 
45 
 
50. Katz, D.J., J.C. Stanley, and G.B. Zelenock, Gender differences in abdominal aortic aneurysm 
prevalence, treatment, and outcome. J Vasc Surg, 1997. 25(3): p. 561-8. 
51. Lederle, F.A., G.R. Johnson, and S.E. Wilson, Abdominal aortic aneurysm in women. J Vasc 
Surg, 2001. 34(1): p. 122-6. 
52. Lederle, F.A., et al., The aneurysm detection and management study screening program: 
validation cohort and final results. Aneurysm Detection and Management Veterans Affairs 
Cooperative Study Investigators. Arch Intern Med, 2000. 160(10): p. 1425-30. 
53. Yeap, B.B., et al., Associations of total testosterone, sex hormone-binding globulin, calculated 
free testosterone, and luteinizing hormone with prevalence of abdominal aortic aneurysm in 
older men. J Clin Endocrinol Metab, 2010. 95(3): p. 1123-30. 
54. Ailawadi, G., et al., Gender differences in experimental aortic aneurysm formation. Arterioscler 
Thromb Vasc Biol, 2004. 24(11): p. 2116-22. 
55. Cho, B.S., et al., Decreased collagen and increased matrix metalloproteinase-13 in 
experimental abdominal aortic aneurysms in males compared with females. Surgery, 2009. 
147(2): p. 258-67. 
56. Labrie, F., et al., Is dehydroepiandrosterone a hormone? J Endocrinol, 2005. 187(2): p. 169-96. 
57. Randall, D., W. Burggren, and K. French, Eckert animal physiology:mechansims and 
adaptations 5th edition. 2001. 
58. Kaufman, J.M. and A. Vermeulen, The decline of androgen levels in elderly men and its clinical 
and therapeutic implications. Endocr Rev, 2005. 26(6): p. 833-76. 
59. Riggs, B.L., S. Khosla, and L.J. Melton, 3rd, Sex steroids and the construction and conservation 
of the adult skeleton. Endocr Rev, 2002. 23(3): p. 279-302. 
60. Bhasin, S., Female androgen deficiency syndrome--an unproven hypothesis. J Clin Endocrinol 
Metab, 2005. 90(8): p. 4970-2. 
61. Wierman, M.E., et al., Androgen therapy in women: an Endocrine Society Clinical Practice 
guideline. J Clin Endocrinol Metab, 2006. 91(10): p. 3697-710. 
62. Mangelsdorf, D.J., et al., The nuclear receptor superfamily: the second decade. Cell, 1995. 
83(6): p. 835-9. 
63. Lee, D.K. and C. Chang, Endocrine mechanisms of disease: Expression and degradation of 
androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab, 2003. 88(9): 
p. 4043-54. 
64. Heinlein, C.A. and C. Chang, The roles of androgen receptors and androgen-binding proteins 
in nongenomic androgen actions. Mol Endocrinol, 2002. 16(10): p. 2181-7. 
65. Losel, R. and M. Wehling, Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol, 
2003. 4(1): p. 46-56. 
66. Lyon, M.F. and S.G. Hawkes, X-linked gene for testicular feminization in the mouse. Nature, 
1970. 227(5264): p. 1217-9. 
REFERENCES 
46 
 
67. Gaspar, M.L., et al., A single base deletion in the Tfm androgen receptor gene creates a short-
lived messenger RNA that directs internal translation initiation. Proc Natl Acad Sci U S A, 
1991. 88(19): p. 8606-10. 
68. Kerkhofs, S., et al., Androgen receptor knockout and knock-in mouse models. J Mol Endocrinol, 
2009. 42(1): p. 11-7. 
69. Sato, T., et al., Late onset of obesity in male androgen receptor-deficient (AR KO) mice. 
Biochem Biophys Res Commun, 2003. 300(1): p. 167-71. 
70. Lin, H.Y., et al., Insulin and leptin resistance with hyperleptinemia in mice lacking androgen 
receptor. Diabetes, 2005. 54(6): p. 1717-25. 
71. De Gendt, K., et al., A Sertoli cell-selective knockout of the androgen receptor causes 
spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A, 2004. 101(5): p. 1327-32. 
72. Notini, A.J., et al., Genomic actions of the androgen receptor are required for normal male 
sexual differentiation in a mouse model. J Mol Endocrinol, 2005. 35(3): p. 547-55. 
73. Kawano, H., et al., Suppressive function of androgen receptor in bone resorption. Proc Natl 
Acad Sci U S A, 2003. 100(16): p. 9416-21. 
74. Yeh, S., et al., Generation and characterization of androgen receptor knockout (ARKO) mice: 
an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S 
A, 2002. 99(21): p. 13498-503. 
75. Hu, Y.C., et al., Subfertility and defective folliculogenesis in female mice lacking androgen 
receptor. Proc Natl Acad Sci U S A, 2004. 101(31): p. 11209-14. 
76. Shiina, H., et al., Premature ovarian failure in androgen receptor-deficient mice. Proc Natl 
Acad Sci U S A, 2006. 103(1): p. 224-9. 
77. Walters, K.A., et al., Female mice haploinsufficient for an inactivated androgen receptor (AR) 
exhibit age-dependent defects that resemble the AR null phenotype of dysfunctional late follicle 
development, ovulation, and fertility. Endocrinology, 2007. 148(8): p. 3674-84. 
78. Walters, K.A., et al., Subfertile female androgen receptor knockout mice exhibit defects in 
neuroendocrine signaling, intraovarian function, and uterine development but not uterine 
function. Endocrinology, 2009. 150(7): p. 3274-82. 
79. Dubey, R.K., S.P. Tofovic, and E.K. Jackson, Cardiovascular pharmacology of estradiol 
metabolites. J Pharmacol Exp Ther, 2004. 308(2): p. 403-9. 
80. Mendelsohn, M.E. and R.H. Karas, The protective effects of estrogen on the cardiovascular 
system. N Engl J Med, 1999. 340(23): p. 1801-11. 
81. Guyton and Hall, Textbook of medical physiology 10th edition. 2000. 
82. Mendelsohn, M.E. and R.H. Karas, Rapid progress for non-nuclear estrogen receptor signaling. 
J Clin Invest, 2010. 120(7): p. 2277-9. 
83. Mooberry, S.L., Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist 
Updat, 2003. 6(6): p. 355-61. 
REFERENCES 
47 
 
84. Vandenput, L., et al., Androgens and glucuronidated androgen metabolites are associated with 
metabolic risk factors in men. J Clin Endocrinol Metab, 2007. 92(11): p. 4130-7. 
85. Tivesten, A., et al., Low serum testosterone and high serum estradiol associate with lower 
extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll 
Cardiol, 2007. 50(11): p. 1070-6. 
86. Muller, M., et al., Endogenous sex hormones and progression of carotid atherosclerosis in 
elderly men. Circulation, 2004. 109(17): p. 2074-9. 
87. Makinen, J., et al., Increased carotid atherosclerosis in andropausal middle-aged men. J Am 
Coll Cardiol, 2005. 45(10): p. 1603-8. 
88. Hak, A.E., et al., Low levels of endogenous androgens increase the risk of atherosclerosis in 
elderly men: the Rotterdam study. J Clin Endocrinol Metab, 2002. 87(8): p. 3632-9. 
89. van den Beld, A.W., et al., Endogenous hormones and carotid atherosclerosis in elderly men. 
Am J Epidemiol, 2003. 157(1): p. 25-31. 
90. Jones, T.H., Testosterone deficiency: a risk factor for cardiovascular disease? Trends 
Endocrinol Metab, 2010. 21(8): p. 496-503. 
91. Khaw, K.T., et al., Endogenous testosterone and mortality due to all causes, cardiovascular 
disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-
Norfolk) Prospective Population Study. Circulation, 2007. 116(23): p. 2694-701. 
92. Laughlin, G.A., E. Barrett-Connor, and J. Bergstrom, Low serum testosterone and mortality in 
older men. J Clin Endocrinol Metab, 2008. 93(1): p. 68-75. 
93. Tivesten, A., et al., Low serum testosterone and estradiol predict mortality in elderly men. J 
Clin Endocrinol Metab, 2009. 94(7): p. 2482-8. 
94. Yeap, B.B., et al., Lower testosterone levels predict incident stroke and transient ischemic 
attack in older men. J Clin Endocrinol Metab, 2009. 94(7): p. 2353-9. 
95. Shahani, S., M. Braga-Basaria, and S. Basaria, Androgen deprivation therapy in prostate cancer 
and metabolic risk for atherosclerosis. J Clin Endocrinol Metab, 2008. 93(6): p. 2042-9. 
96. Levine, G.N., et al., Androgen-deprivation therapy in prostate cancer and cardiovascular risk: 
a science advisory from the American Heart Association, American Cancer Society, and 
American Urological Association: endorsed by the American Society for Radiation Oncology. 
Circulation, 2010. 121(6): p. 833-40. 
97. Keating, N.L., A.J. O'Malley, and M.R. Smith, Diabetes and cardiovascular disease during 
androgen deprivation therapy for prostate cancer. J Clin Oncol, 2006. 24(27): p. 4448-56. 
98. Saigal, C.S., et al., Androgen deprivation therapy increases cardiovascular morbidity in men 
with prostate cancer. Cancer, 2007. 110(7): p. 1493-500. 
99. Larsen, B.A., et al., Effect of testosterone on atherogenesis in cholesterol-fed rabbits with 
similar plasma cholesterol levels. Atherosclerosis, 1993. 99(1): p. 79-86. 
REFERENCES 
48 
 
100. Bruck, B., et al., Gender-specific differences in the effects of testosterone and estrogen on the 
development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol, 1997. 17(10): p. 
2192-9. 
101. Alexandersen, P., et al., Natural androgens inhibit male atherosclerosis: a study in castrated, 
cholesterol-fed rabbits. Circ Res, 1999. 84(7): p. 813-9. 
102. Elhage, R., et al., 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient 
mice. Arterioscler Thromb Vasc Biol, 1997. 17(11): p. 2679-84. 
103. McRobb, L., D.J. Handelsman, and A.K. Heather, Androgen-induced progression of arterial 
calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. 
Endocrinology, 2009. 150(2): p. 841-8. 
104. Nathan, L., et al., Testosterone inhibits early atherogenesis by conversion to estradiol: critical 
role of aromatase. Proc Natl Acad Sci U S A, 2001. 98(6): p. 3589-93. 
105. Jones, T.H. and F. Saad, The effects of testosterone on risk factors for, and the mediators of, the 
atherosclerotic process. Atherosclerosis, 2009. 207(2): p. 318-27. 
106. Henriques, T.A., et al., Orchidectomy, but not ovariectomy, regulates angiotensin II-induced 
vascular diseases in apolipoprotein E-deficient mice. Endocrinology, 2004. 145(8): p. 3866-72. 
107. Rosner, W., et al., Position statement: Utility, limitations, and pitfalls in measuring 
testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab, 2007. 92(2): p. 
405-13. 
108. Bachmann, G., et al., Female androgen insufficiency: the Princeton consensus statement on 
definition, classification, and assessment. Fertil Steril, 2002. 77(4): p. 660-5. 
109. Wild, R.A., et al., Assessment of cardiovascular risk and prevention of cardiovascular disease 
in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess 
and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab, 2010. 95(5): p. 
2038-49. 
110. Nestler, J.E., Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med, 
2008. 358(1): p. 47-54. 
111. Christakou, C.D. and E. Diamanti-Kandarakis, Role of androgen excess on metabolic 
aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health 
(Lond Engl), 2008. 4(6): p. 583-94. 
112. Corbould, A., Effects of androgens on insulin action in women: is androgen excess a component 
of female metabolic syndrome? Diabetes Metab Res Rev, 2008. 24(7): p. 520-32. 
113. Legro, R.S., Polycystic ovary syndrome and cardiovascular disease: a premature association? 
Endocr Rev, 2003. 24(3): p. 302-12. 
114. Adams, M.R., J.K. Williams, and J.R. Kaplan, Effects of androgens on coronary artery 
atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler 
Thromb Vasc Biol, 1995. 15(5): p. 562-70. 
REFERENCES 
49 
 
115. Obasanjo, I.O., T.B. Clarkson, and D.S. Weaver, Effects of the anabolic steroid nandrolone 
decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. 
Metabolism, 1996. 45(4): p. 463-8. 
116. von Dehn, G., et al., Atherosclerosis in apolipoprotein E-deficient mice is decreased by the 
suppression of endogenous sex hormones. Horm Metab Res, 2001. 33(2): p. 110-4. 
117. Hodgin, J.B. and N. Maeda, Minireview: estrogen and mouse models of atherosclerosis. 
Endocrinology, 2002. 143(12): p. 4495-501. 
118. Xing, D., et al., Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc 
Biol, 2009. 29(3): p. 289-95. 
119. Rossouw, J.E., et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal 
women: principal results From the Women's Health Initiative randomized controlled trial. 
JAMA, 2002. 288(3): p. 321-33. 
120. Hulley, S., et al., Randomized trial of estrogen plus progestin for secondary prevention of 
coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement 
Study (HERS) Research Group. JAMA, 1998. 280(7): p. 605-13. 
121. Barrett-Connor, E., Clinical review 162: cardiovascular endocrinology 3: an epidemiologist 
looks at hormones and heart disease in women. J Clin Endocrinol Metab, 2003. 88(9): p. 4031-
42. 
122. Dubey, R.K., et al., Hormone replacement therapy and cardiovascular disease: what went 
wrong and where do we go from here? Hypertension, 2004. 44(6): p. 789-95. 
123. Arnal, J.F., et al., Estrogens in vascular biology and disease: where do we stand today? Curr 
Opin Lipidol, 2007. 18(5): p. 554-60. 
124. Clarkson, T.B. and S.E. Appt, Controversies about HRT--lessons from monkey models. 
Maturitas, 2005. 51(1): p. 64-74. 
125. Holm, P., et al., The direct antiatherogenic effect of estrogen is present, absent, or reversed, 
depending on the state of the arterial endothelium. A time course study in cholesterol-clamped 
rabbits. Circulation, 1999. 100(16): p. 1727-33. 
126. Arnal, J.F., et al., Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol, 2010. 
30(8): p. 1506-12. 
127. Nathan, L., et al., Estradiol inhibits leukocyte adhesion and transendothelial migration in 
rabbits in vivo : possible mechanisms for gender differences in atherosclerosis. Circ Res, 1999. 
85(4): p. 377-85. 
128. Rodriguez, E., et al., 17Beta-estradiol inhibits the adhesion of leukocytes in TNF-alpha 
stimulated human endothelial cells by blocking IL-8 and MCP-1 secretion, but not its 
transcription. Life Sci, 2002. 71(18): p. 2181-93. 
129. Burek, M., et al., Claudin-5 as a novel estrogen target in vascular endothelium. Arterioscler 
Thromb Vasc Biol, 2010. 30(2): p. 298-304. 
REFERENCES 
50 
 
130. Florian, M. and S. Magder, Estrogen decreases TNF-alpha and oxidized LDL induced apoptosis 
in endothelial cells. Steroids, 2008. 73(1): p. 47-58. 
131. Filipe, C., et al., Estradiol accelerates endothelial healing through the retrograde commitment 
of uninjured endothelium. Am J Physiol Heart Circ Physiol, 2008. 294(6): p. H2822-30. 
132. Toutain, C.E., et al., Estrogen receptor alpha expression in both endothelium and hematopoietic 
cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler 
Thromb Vasc Biol, 2009. 29(10): p. 1543-50. 
133. Chandrasekar, B. and J.F. Tanguay, Local delivery of 17-beta-estradiol decreases neointimal 
hyperplasia after coronary angioplasty in a porcine model. J Am Coll Cardiol, 2000. 36(6): p. 
1972-8. 
134. Strehlow, K., et al., Estrogen increases bone marrow-derived endothelial progenitor cell 
production and diminishes neointima formation. Circulation, 2003. 107(24): p. 3059-65. 
135. Iwakura, A., et al., Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization 
of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after 
arterial injury. Circulation, 2003. 108(25): p. 3115-21. 
136. Fontaine, V., et al., Essential role of bone marrow fibroblast growth factor-2 in the effect of 
estradiol on reendothelialization and endothelial progenitor cell mobilization. Am J Pathol, 
2006. 169(5): p. 1855-62. 
137. Geraldes, P., et al., Estrogen regulation of endothelial and smooth muscle cell migration and 
proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb 
Vasc Biol, 2002. 22(10): p. 1585-90. 
138. Sack, M.N., D.J. Rader, and R.O. Cannon, 3rd, Oestrogen and inhibition of oxidation of low-
density lipoproteins in postmenopausal women. Lancet, 1994. 343(8892): p. 269-70. 
139. St Clair, R.W., Effects of estrogens on macrophage foam cells: a potential target for the 
protective effects of estrogens on atherosclerosis. Curr Opin Lipidol, 1997. 8(5): p. 281-6. 
140. Dubey, R.K. and E.K. Jackson, Cardiovascular protective effects of 17beta-estradiol 
metabolites. J Appl Physiol, 2001. 91(4): p. 1868-83. 
141. Chow, R.W., D.J. Handelsman, and M.K. Ng, Minireview: rapid actions of sex steroids in the 
endothelium. Endocrinology, 2010. 151(6): p. 2411-22. 
142. Sutherland, T.E., et al., 2-Methoxyestradiol--a unique blend of activities generating a new class 
of anti-tumour/anti-inflammatory agents. Drug Discov Today, 2007. 12(13-14): p. 577-84. 
143. Dantas, A.P. and K. Sandberg, Does 2-methoxyestradiol represent the new and improved 
hormone replacement therapy for atherosclerosis? Circ Res, 2006. 99(3): p. 234-7. 
144. Barchiesi, F., et al., 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation 
and smooth muscle cell growth via double blockade of the cell cycle. Circ Res, 2006. 99(3): p. 
266-74. 
REFERENCES 
51 
 
145. Tofovic, S.P., et al., Estradiol metabolites attenuate renal and cardiovascular injury induced by 
chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol, 2005. 46(1): p. 25-35. 
146. Tofovic, S.P., et al., Estradiol metabolites attenuate monocrotaline-induced pulmonary 
hypertension in rats. J Cardiovasc Pharmacol, 2005. 46(4): p. 430-7. 
147. Markides, C.S., D. Roy, and J.G. Liehr, Concentration dependence of prooxidant and 
antioxidant properties of catecholestrogens. Arch Biochem Biophys, 1998. 360(1): p. 105-12. 
148. Grier, S.J., A.S. Turner, and M.R. Alvis, The use of dual-energy x-ray absorptiometry in 
animals. Invest Radiol, 1996. 31(1): p. 50-62. 
149. Sjogren, K., et al., Body fat content can be predicted in vivo in mice using a modified dual-
energy X-ray absorptiometry technique. J Nutr, 2001. 131(11): p. 2963-6. 
150. Li, S., X. Li, and Y. Li, Regulation of atherosclerotic plaque growth and stability by 
testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol, 2008. 
49(1): p. 14-8. 
151. Nettleship, J.E., et al., Physiological testosterone replacement therapy attenuates fatty streak 
formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is 
independent of the classic androgen receptor. Circulation, 2007. 116(21): p. 2427-34. 
152. Fan, W., et al., Androgen receptor null male mice develop late-onset obesity caused by 
decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high 
adiponectin secretion. Diabetes, 2005. 54(4): p. 1000-8. 
153. Yeh, S., et al., Abnormal mammary gland development and growth retardation in female mice 
and MCF7 breast cancer cells lacking androgen receptor. J Exp Med, 2003. 198(12): p. 1899-
908. 
154. Traish, A.M., R. Abdou, and K.E. Kypreos, Androgen deficiency and atherosclerosis: The lipid 
link. Vascul Pharmacol, 2009. 51(5-6): p. 303-13. 
155. Nantermet, P., et al., Gene expression analyses in cynomolgus monkeys provides mechanistic 
insight into high-density lipoprotein-cholesterol reduction by androgens in primates. 
Endocrinology, 2008. 149(4): p. 1551-61. 
156. Bourghardt, J., et al., Androgen Receptor-Dependent and Independent Atheroprotection by 
Testosterone in Male Mice. Endocrinology, 2010. 
157. Henriques, T., et al., Androgen increases AT1a receptor expression in abdominal aortas to 
promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice. Arterioscler Thromb 
Vasc Biol, 2008. 28(7): p. 1251-6. 
158. Tofovic, S.P., et al., 2-Methoxyestradiol mediates the protective effects of estradiol in 
monocrotaline-induced pulmonary hypertension. Vascul Pharmacol, 2006. 45(6): p. 358-67. 
159. Hodgin, J.B., et al., Estrogen receptor alpha is a major mediator of 17beta-estradiol's 
atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest, 2001. 107(3): p. 333-40. 
REFERENCES 
52 
 
160. Zacharia, L.C., et al., Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: 
direct evidence from catechol-O-methyltransferase-knockout mice. Circulation, 2003. 108(24): 
p. 2974-8. 
161. Sibonga, J.D., et al., Dose-response effects of 2-methoxyestradiol on estrogen target tissues in 
the ovariectomized rat. Endocrinology, 2003. 144(3): p. 785-92. 
162. Seeger, H., A.O. Mueck, and T.H. Lippert, Effect of estradiol metabolites on prostacyclin 
synthesis in human endothelial cell cultures. Life Sci, 1999. 65(13): p. PL167-70. 
163. Basaria, S., et al., Adverse events associated with testosterone administration. N Engl J Med, 
2010. 363(2): p. 109-22. 
164. Daskivich, T.J. and W.K. Oh, Recent progress in hormonal therapy for advanced prostate 
cancer. Curr Opin Urol, 2006. 16(3): p. 173-8. 
165. Gillatt, D., Antiandrogen treatments in locally advanced prostate cancer: are they all the same? 
J Cancer Res Clin Oncol, 2006. 132 Suppl 1: p. S17-26. 
166. Taylor, L.G., S.E. Canfield, and X.L. Du, Review of major adverse effects of androgen-
deprivation therapy in men with prostate cancer. Cancer, 2009. 115(11): p. 2388-99. 
167. Bhasin, S. and R. Jasuja, Selective androgen receptor modulators as function promoting 
therapies. Curr Opin Clin Nutr Metab Care, 2009. 12(3): p. 232-40. 
168. Bernini, G.P., et al., Endogenous androgens and carotid intimal-medial thickness in women. J 
Clin Endocrinol Metab, 1999. 84(6): p. 2008-12. 
169. Golden, S.H., et al., Endogenous postmenopausal hormones and carotid atherosclerosis: a 
case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol, 2002. 
155(5): p. 437-45. 
170. Kaczmarek, A., et al., The association of lower testosterone level with coronary artery disease 
in postmenopausal women. Int J Cardiol, 2003. 87(1): p. 53-7. 
171. Montalcini, T., et al., Role of endogenous androgens on carotid atherosclerosis in non-obese 
postmenopausal women. Nutr Metab Cardiovasc Dis, 2007. 17(10): p. 705-11. 
172. Laughlin, G.A., V. Goodell, and E. Barrett-Connor, Extremes of endogenous testosterone are 
associated with increased risk of incident coronary events in older women. J Clin Endocrinol 
Metab, 2010. 95(2): p. 740-7. 
173. Patel, S.M., et al., Higher serum testosterone concentration in older women is associated with 
insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab, 
2009. 94(12): p. 4776-84. 
174. Braunstein, G.D., The Endocrine Society Clinical Practice Guideline and The North American 
Menopause Society position statement on androgen therapy in women: another one of Yogi's 
forks. J Clin Endocrinol Metab, 2007. 92(11): p. 4091-3. 
175. Buster, J.E., et al., Testosterone patch for low sexual desire in surgically menopausal women: a 
randomized trial. Obstet Gynecol, 2005. 105(5 Pt 1): p. 944-52. 
REFERENCES 
53 
 
176. Shifren, J.L., et al., Transdermal testosterone treatment in women with impaired sexual function 
after oophorectomy. N Engl J Med, 2000. 343(10): p. 682-8. 
177. Miller, K.K., et al., Effects of testosterone therapy on cardiovascular risk markers in androgen-
deficient women with hypopituitarism. J Clin Endocrinol Metab, 2007. 92(7): p. 2474-9. 
178. Turgeon, J.L., et al., Complex actions of sex steroids in adipose tissue, the cardiovascular 
system, and brain: Insights from basic science and clinical studies. Endocr Rev, 2006. 27(6): p. 
575-605. 
 
 
